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ABSTRACT
For decades α-synuclein has been the focus of research because of its association with Parkinson’s
disease and other types of dementia. Recently the focus has shifted from attempting to understand
the mode of toxicity of α-synuclein aggregates to trying to identify α-synuclein’s healthy physio-
logical function. It has been identified that α-synuclein interacts with the SNARE complex and
assists in SNARE-mediated membrane fusion. Utilizing two novel single molecule assays we are
able to determine how α-synuclein enhances SNARE activity. α-synuclein has two major domains:
one that buries itself in the phospholipid head groups of a membrane and another that binds to the
v -SNARE VAMP2. By using both of these domains α-synuclein can tether vesicles more securely
to the plasma membrane providing the SNARE complex more time to form properly.
1
CHAPTER 1. INTRODUCTION
1.1 Perspective on the field
One of the defining qualities that makes us human is our ability to reason. It is what separates
us from many other species and has allowed us to make such progress. We value this and consider
it a vital quality of who we are. Our memories, experiences, and relationships are also fundamental
to who we are as individuals. These attributes arise from the structure, organization, and health
of our minds. This has driven the exploration of psychology and neurobiology for decades, if not
centuries. It is also why research into detriments of our reasoning and memory are so crucial
to humanity. When we lose these faculties, part of what makes us human is lost. It alters our
perception of the world around us and our ability to function autonomously.
There are many psychoses that affect how we think; the majority arising from alterations in
intercellular communication between neurons. Defects in this process can lead to many neural dys-
functions ranging from seizures, bipolar disorder, and schizophrenia, to Alzheimer’s, and Parkin-
son’s. Some arise because of intercellular communication being overactive, while others because it
is inhibited. Normally, intercellular communication is achieved by a neurotransmitter-laden vesicle
fusing with the neuron’s outer membrane. The vesicle is brought near to the plasma membrane
and the two are gradually fused one membrane at a time until there is a channel formed from
the vesicle through the plasma membrane allowing the neurotransmitter to escape. This release of
transmitters is received by surrounding neurons resulting in signal transduction.
The energy and direction for this process is believed to be provided by the SNARE
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex (Figure 1.1). This
complex is made up of two halves: one half on the incoming vesicle (v-SNARE), and the other on
the plasma membrane (t-SNARE). The v -SNARE is composed of a single component: VAMP2.
The t-SNARE is an assembly of syntaxin-1A and SNAP-25. All three proteins have SNARE
2





Figure 1.1: A diagram of SNARE-mediated membrane fusion. The v -SNARE, VAMP2 located
on the incoming vesicle initiates binding to the t-SNARE Syntaxin-1A and SNAP-25 pair on the plasma
membrane. This hold the vesicle in the docking stage. The v - and t- SNARE then start to form a coiled-coil
drawing the vesicle closer to the plasma membrane until the outer leaflets of the two membranes merge.
This is the hemi-fusion state. The completion of the SNARE complex’s coiled-coil drives the merger of the
inner leaflets on the membranes and forms the small fusion pore. This pore then expands through the large
pore state and ends with the vesicle membrane having fully merged with the plasma membrane.
3
motifs that allows them to interact. VAMP2 and syntaxin-1A each have one SNARE motif and
SNAP-25 has two. When all four of the domains come into contact they form a coiled-coil. The
transmembrane domains of VAMP2 and syntaxin-1A act as anchors in the opposing membranes
allowing the formation of this structure to funnel energy toward membrane fusion (Brunger (2005);
Jahn and Scheller (2006)).
This process is regulated by a plethora of auxiliary factors. Some stabilize vesicles close to the
plasma membrane. Others pause SNARE complex formation inhibiting non-synchronous release.
Additional factors sense the influx of Ca2+, overcome or remove the halting factors, and induce
release. Still other factors have been shown to interact with the SNARE complex, but their function
is yet unknown.
One such protein is α-synuclein. It first gained interest when it was found to be the major
component of large aggregates in patients with Parkinson’s (Spillantini et al. (1998); Spillantini
et al. (1998)). It was assumed that these aggregates were the cause of dementia. α-synuclein
was quickly introduced to animal models with the goal of defining how aggregates were causing
dementia. Overexpression of α-synuclein in animals introduced the same effects that were seen in
patients (Maries et al. (2003)). They had large aggregates in the brain and displayed Parkinson’s
like behavior. When overexpression of α-synuclein was induced in cultured neurons it was found to
be toxic and led to cellular death (Zhou et al. (2000)). The first insight into how α-synuclein might
be causing dementia came when it was found to be localized to the presynaptic membrane and
that overexpression reduced stimulated exocytosis from chromaffin cells (Maroteaux et al. (1988)).
Investigation into possible binding partners confirmed that α-synuclein interacted with the SNARE
complex (Burré et al. (2010)). Immunoprecipitation of α-synuclein could pull the SNARE complex
out of solution and the SNARE complex could also pull-down α-synuclein (Burré et al. (2010)).
This initiated many in vitro experiments that sought to identify the molecular mechanism of
α-synuclein aggregates inhibiting SNARE-mediated fusion. Some groups focused on α-synuclein’s
amphipathic nature identifying that α-synuclein had increased affinity for membranes with neg-
ative charge (Middleton and Rhoades (2010)). Familial mutants that lead to the early onset of
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Parkinson’s disease demonstrate shifts in their membrane affinity; demonstrating that membrane
affinity was somehow significant. Others studied its ability to sense and produce membrane cur-
vature (Varkey et al. (2010)). This implicated that it might be involved in fusion pore formation
and in fact it was confirmed that α-synuclein could indeed form pores in membranes. Still others
focused on how α-synuclein aggregates could directly affect the SNARE complex, demonstrating
that they disrupt SNARE complex formation even in nanomolar quantities (Choi et al. (2013)).
All of these studies were focused on the mechanism of toxicity for α-synuclein and were missing
a very fundamental question. If α-synuclein’s only physiological function is to aggregate and cause
toxicity, why should organisms go through the effort of producing α-synuclein? It is highly expressed
in neurons. It has been estimated to be expressed in upwards of 5 uM in some studies making it one
of the highest expressed proteins in neurons (Iwai et al. (1995)). α-synuclein is then transported
down the axon where it is localized in the presynaptic region. This is a tremendous amount of
energy for organisms to go through to produce something that is going to be detrimental. If this
were its only function, it would have been eliminated by evolution long ago. The question then is,
what is the function of α-synuclein?
More recently, evidence has begun to accumulate for how α-synuclein might be beneficial. One
group observed in mice that retention of α-synuclein prolonged neural health over those with α-
synuclein knocked-out (Burré et al. (2010)). Another group observed that α-synuclein’s ability to
bind membranes and its ability to polymerize give it the unique ability to cluster vesicles (Diao
et al. (2013)). They hypothesize that α-synuclein may be creating rafts of vesicles and chaper-
oning them to the plasma membrane facilitating the creation of a pool of vesicles ready to be
used. Another group observed that it could help the assembly of SNARE complexes (Burré et al.
(2014)). Another suggested that α-synuclein could enhance SNARE-dependent membrane merger
at specific concentrations bridging the concepts that α-synuclein is beneficial and toxic (Lou et al.
(2017)). More recently, another group showed that in vivo α-synuclein increased the amount of
neurotransmitter released from cells and hypothesized that it may function as a fusion pore dilator
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(Logan et al. (2017)). This is all getting very close to identifying what the possible natural function
of α-synuclein is.
What was necessary to continue this investigation was the ability to have a minimalistic view
of how α-synuclein effected each step in membrane merger and fusion. This had yet to be done
because of the vast challenge of observing discrete steps in membrane fusion. It required a suit-
able system of membrane models of the in vivo environment (curved vesicles and a nearly planer
bilayer). It is also necessary to record this process with physiologically relevant millisecond time-
resolution. Attempts were made to do this with x-ray crystallography, electron microscopy, and
other biophysical techniques. While insight was gained from those studies, they were not able to
capture the effects of the SNARE complex on membrane merger in real-time.
1.2 Progress
We achieved this by using TIRF (total internal reflection fluorescence) microscopy with vesicles,
and a supported bilayer. To observe discrete steps in membrane fusion, individual vesicles have to
be observed so that the signal that they generate as they pass through each stage in membrane
fusion is not lost in the average of the overall activity. TIRF microscopy uses a quartz prism to
direct and deflect lasers off a quartz slide at a very precise angle that creates a wave of luminescence
called the evanescent wave. This wave of fluorescence only travels ∼200 nm into the solution. It
does not illuminate the majority of the solution creating a very high signal to noise level. This
in conjunction with fluorophores allows for single vesicle to be observed granting us our goal of
observing a single vesicles as they progress through membrane fusion (Figure 1.1).
In many cases having only the surface illuminated would be a severe limitation, but for our
application it is ideal. Only the surface being illuminated is optimal for our assay because all the
activity for our system is very near the quartz surface. The PEG supports are about 6 nm high
and the bilayer is 4-5 nm thick. The vesicles are 100 nm in diameter, so when they are near the
supported bilayer they are well within the 200 nm deep evanescent wave. This is perfect for both
refraining from illuminating the majority of the vesicles in solution and amplifying the signal we
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are desiring to observe. In either of the cases where the fluorescent reporter is a lipid or soluble
fluorophore, they are progressing further into the evanescent wave as the membranes merge.
Regardless of how optimal TIRF microscopy is for providing a unique perspective into how α-
synuclein affects discrete stages in membrane fusion, it is inconsequential if it can not be recorded
and analyzed. That requires a camera that is both capable of detecting sparse numbers of photons
and measuring on a time-scale relevant for membrane fusion. The charge-coupled device (CCD)
camera coupled to our TIRF microscope allows us to record at 20 ms per frame. Exploiting this
technology has allowed us to capture individual vesicles in the membrane fusion process. From our
observations we have determined that α-synuclein’s primary role in membrane fusion is to stabilize
vesicles on the plasma membrane allowing more secure SNARE complexes to form and to increase
the surface area with which the SNARE complexes can interact. When α-synuclein tethers a vesicle
to the bilayer, it becomes drawn out into a discus shape lying parallel to the plasma membrane.
This promotes multiple fusion pores to form on each vesicle. With this we are able to contribute
to the growing perspective on what α-synuclein’s native function is and are able to propose areas
of future investigation.
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2.1 Abstract
Recently, Parkinson’s disease-associated α-synuclein has emerged as an important regulator
for SNARE-dependent vesicle fusion. However, it is controversial if excessive accumulation of α-
synuclein, even in the absence of aggregation, impairs neurotransmission. Here we use a single
vesicle fusion assay with ms time resolution capable of dissecting the impact of α-synuclein on
each step of membrane fusion. Unlike the previous results from various in vitro, cellular, and in
vivo studies, we find that non-aggregated α-synuclein promotes vesicle merger even at exorbitant
concentrations. The enhancement has been seen as much as 13 fold. Delving into the kinetics
of the intermediate states for vesicle fusion reveals that α-synuclein stimulates vesicle docking
without altering the dynamics of bilayer merger (lipid mixing). However, minute amounts of soluble
aggregated species abolish SNARE-dependent bilayer merger completely. Thus, the results show




Neurotransmitter release is the foundation of thought in the central nervous system. The brain
is comprised of networks of neurons joined together via synapses. Communication between these
neurons is mediated by vesicle fusion releasing neurotransmitters at the synapses. Defects in the
regulation of neurotransmission are believed to be the primary cause for many neurological diseases.
For example, the main cause for schizophrenia is thought to be over-release of dopamine, while for
epilepsy it may be the under release of adenosine and glycine (Boison et al. (2012)). The key
to a better understanding of neurological diseases lies in a more complete understanding of the
molecular machine responsible for synaptic vesicle fusion.
The SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment Protein Receptor) proteins
are believed to mediate synaptic vesicle fusion (Söllner et al. (1993); Weber et al. (1998); Jahn and
Scheller (2006)). Vesicle-associated v-SNARE forms a helical coiled coil with the target plasma
membrane t-SNARE to drive membrane fusion (Poirier et al. (1998); Sutton et al. (1998)). Neuro-
transmitters are released from the vesicle through the fusion pore to the synaptic cleft (Breckenridge
and Almers (1988)). Action potential-evoked vesicle fusion events are synchronized and happen in
less than a millisecond (Sabatini and Regehr (1996)). The synchronous release is achieved through
an exquisite regulation of SNARE complex formation by a host of regulatory proteins including
the Ca2+-sensor, synaptotagmin-1 (Fernandez et al. (2001); Chapman (2002); Lee et al. (2010)).
α-synuclein has long been a protein of great interest because of its pathological aggregation
in neuronal plaque and Lewy bodies, which are associated with Parkinson’s Disease and Lewy
Body Dementia, respectively (Hardy and Gwinn-Hardy (1998); Shimohama et al. (2003); Lee and
Trojanowski (2006); Spillantini et al. (1997)). Despite its medical significance, the normal function
of α-synuclein has been elusive. α-synuclein is a 14 kDa soluble protein that is abundantly present
in the neuron (several µM), particularly in the presynapse (Maroteaux et al. (1988); George et al.
(1995)). Not surprisingly, α-synuclein has been found to play roles in various aspects of vesicle
recycling (Larsen et al. (2006); Nemani et al. (2010); Yavich et al. (2004); Scott and Roy (2012)).
Recently, α-synuclein has emerged as an important regulator for SNARE-dependent vesicle fusion.
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Sudhof and coworkers discovered that α-synuclein promotes SNARE complex formation via
its interaction with v -SNARE VAMP2 (Burré et al. (2010)). Consistent with these results, Lou
et al. (2017) found in an in vitro study that α-synuclein promotes vesicle docking. However,
the proposed positive role of α-synuclein in SNARE-dependent membrane fusion appears to be
at odds with the results from nearly all overexpression studies. The overexpression studies show
that α-synuclein leads to the impairment of neurotransmission (Larsen et al. (2006); Nemani et al.
(2010); Lundblad et al. (2012); Phan et al. (2017)). Although it was shown that overexpressed
α-synuclein disturbs vesicle pools (Nemani et al. (2010)), its direct interference with the SNARE
complex formation cannot be ruled out. Furthermore, several in vitro studies have shown that
excessive α-synuclein severely inhibits SNARE-dependent membrane fusion (DeWitt and Rhoades
(2013); Lai et al. (2014)). Thus, the results raise the question, is the α-synuclein function acutely
concentration-dependent? Furthermore, is excessive α-synuclein a cause of impaired neurotrans-
mission? If true, then it would have serious medical implications. Similarly, for Alzheimer’s disease,
excessive but non-aggregated amyloid-β has been suspected for the impaired neurotransmission and
early symptoms of the disease (Bergamaschini et al. (1999); McLaurin and Lai (2011)).
To sort out discrepancies among the results, we used an in vitro single vesicle-to-supported
bilayer merger assay (Kim and Shin (2017)), in which, unlike the cellular environment, a precise
variation of α-synuclein concentration is possible. Moreover, this assay provides the opportunity
to dissect the impact of α-synuclein on individual vesicle fusion steps such as vesicle docking and
bilayer merger along the membrane fusion pathway. The assay has proven effective in analyzing
single bilayer merger events in a natural, millisecond timescale between vesicles and a supported-
bilayer (Kim and Shin (2017)).
Using this assay, we have found that α-synuclein enhances vesicle docking by a factor of 10
at an excessive 20 µM concentration, which is as much as 4 times higher than normal cellular
levels. These results contradict the notion that excessive α-synuclein impairs vesicle fusion and
neurotransmission, which is previously supported by overexpression as well as the in vitro studies.






Figure 2.1: Single vesicle-to-supported bilayer merger assay distinguishes vesicle docking from
bilayer merger in real time. (A) Schematic diagram of the single vesicle-to-supported bilayer merger
assay. v-vesicles are labeled with 1 mol % lipid-dye DiI. The t-bilayer is stabilized by a PEG (polyethylene
glycol) cushion between the bilayer and the quartz slide. When v-vesicles dock onto the t-bilayer through
SNARE zippering, the TIRF laser excites the fluorescent dye allowing the individual v-vesicle to be visualized.
(B) Lipid diffusion on the bilayer surface due to bilayer merger. The large box contains a raw image of the
docked and merging vesicles. The small box contains a zoomed image of lipid diffusion event.
membrane fusion is largely on vesicle docking with no significant changes in the dynamics of bilayer
merger.
2.3 Results
2.3.1 Single Vesicle-to-Supported Bilayer Merger Assay
To investigate the effect of α-synuclein on SNARE-dependent vesicle fusion, we analyzed the
merger of single v -SNARE VAMP2-reconstituted vesicles (v -vesicles) to the supported bilayer re-
constituted with t-SNAREs syntaxin-1A and SNAP-25 (t-bilayer) with TIRF microscopy (Fig-
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ure 2.1A). Similar experimental platforms were previously used by several groups to investigate
SNARE-dependent membrane fusion (Fix et al. (2004); Karatekin et al. (2010); Liu et al. (2005);
Kiessling et al. (2017)). We adopted this method instead of the vesicle-to-vesicle fusion method
(Yoon et al. (2006); Lou et al. (2017)) because the supported bilayer better mimics the planar ge-
ometry of the plasma membrane. The planar t-bilayer rests on polyethylene glycol (PEG) supports
to maintain the membrane fluidity (Karatekin et al. (2010); Kim and Shin (2017)). The v-vesicles
are doped with 1 mol % lipid-dye DiI as a reporter for the diffusion of phospholipid molecules from
a v-vesicle onto the planar bilayer upon the merging of lipid bilayers.
Immediately after v-vesicles were flowed over the supported bilayer in the microfluidic chambers,
vesicle docking and bilayer merger events were filmed every 20 msec. for 30 sec. Individual docking
and subsequent bilayer merger events could be resolved from each other. When a vesicle is tethered
to the surface, docking caused a sharp increase in fluorescence, but when the bilayers merged,
the lipids diffused in the two-dimensional (2D) surface creating a steep decline in fluorescence at
the centroid (Figure 2.1B and Figure 2.2A-C). The cumulative number of vesicle docking events
(Figure 2.2D) and the delay between docking and bilayer merger were recorded for further analysis
of the kinetics (Figure 2.2E). We found that about 40-60% of docked vesicles exhibit bilayer merger
(Figure 2.2D & E). Of those events, nearly 70% showed instant bilayer merger (within the first 20
msec., while 30% were scattered over the remainder of the 30 sec. recording time (Figure 2.2E).
2.3.2 α-synuclein Enhances Vesicle Docking in all Concentrations Studied up to 20 µM
Recombinant α-synuclein was expressed in E. coli as a GST-fusion protein and it was purified
with gel-filtration chromatography after cleavage from the GST-tag. SDS-PAGE gels and west-
ern blots showed that the protein still had trace amounts of high molecular weight bands after
one round of gel filtration (Figure 2.3A). Thus, the sample was subjected to a subsequent round
of gel filtration to attain a higher purity. When this highly purified, twice filtered α-synuclein
was included in the single-vesicle assay, it enhanced SNARE-dependent vesicle docking events in
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Figure 2.2: Single vesicle-to-supported bilayer merger assay example data. (A) Representative
trace of the instant merger. (B) Representative trace of the delayed merger. (C) Representative trace of
docking only. The fluorescence decay due to photo-bleaching is at least 5 times slower than the decrease
due to lipid diffusion. Further classification of instant merger, delayed merger, and docking only events
are defined in the Materials and Methods section. (D) Representative cumulative plot of docking events
occurring within a single viewing area for 30 sec. The black line indicates cumulative docking events without
α-synuclein. The red line indicates those with twice purified α-synuclein at 10 µM. (E) Representative
scatter plot of the delay from docking to bilayer merger. Bilayer merger events that occur within the first















































































Figure 2.3: Non-aggregated α-synuclein enhances vesicle docking activity even at excessive
concentrations. (A) SDS-PAGE and western blot analysis of purified recombinant α-synuclein. A 12%
SDS-PAGE gel containing α-synuclein through the two rounds of gel filtration: Lane 1 contains α-synuclein
after the 1st round of gel filtration. Lane 2 contains α-synuclein after the 2nd round of gel filtration (left
panel). A western blot of α-synuclein through the two rounds of gel filtration (right panel). The lane order
was the same as SDS-PAGE. Bracket encloses higher molecular weight α-synuclein bands observed only in the
sample from a single round of gel filtration. (B) Analysis of vesicle docking with twice purified α-synuclein
(lane 2 in A). The number of docking events for each α-synuclein concentration were normalized relative
to that without α-synuclein. The dashed line represents the vesicle docking activity of SNAREs without
α-synuclein. Studies without VAMP2 were done by flowing v-liposomes without VAMP2 reconstituted in
them along with 10 µM α-synuclein over the supported t-bilayer. No events were observed. In total 3,148
docking events from 82 independent measurements were analyzed. (C) Analysis of vesicle docking with one-
time purified α-synuclein (lane 1 in A). The number of docking events from each α-synuclein concentration
was normalized with respect to those without α-synuclein. The dashed line represents the docking activity
of SNAREs without α-synuclein. Studies without VAMP2 were done in the same way as in B. A total of
6,249 vesicle docking events from 65 independent measurements were analyzed.
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as much as 13 fold at 10 µM and 10 fold even at 20 µM. The results were surprising and appear
to contradict previous results from overexpression studies (Nemani et al. (2010)) and those from
several in vitro studies (DeWitt and Rhoades (2013), Lai et al. (2014)), where 20 µM α-synuclein
almost completely abolished bilayer merger and subsequent fusion. The SNARE dependence of the
α-synuclein enhancement was tested by removing the SNARE component on the vesicles (VAMP2).
Without VAMP2 membrane docking and merger was abolished. 10 µM α-synuclein did not gen-
erate any events in the absence of VAMP2 demonstrating the SNARE dependence of α-synuclein
enhancement (Figure 2.3B).
This begged the question if the discrepancy between the present and previous results stemmed
from the high molecular weight bands in under-purified samples. To test this, α-synuclein from
the 1st gel filtration, containing small amounts of high molecular weight bands, was used in our
bilayer merger assay. A small enhancement in vesicle docking at lower concentrations was observed.
However, there was a significant inhibition of vesicle docking at α-synuclein concentrations greater
than 5 µM with vesicle docking and bilayer merger activity almost non-observable at 20µM (Fig-
ure 2.3C). This concentration-dependent variation is reminiscent of a previous in vitro study by
Lou et al. (2017) using the single vesicle-to-vesicle fusion assay. The drastic effect from the small
amount of high molecular weight bands from a single round of gel filtration could also explain why
the enhancement of the highly purified α-synuclein plateaued after 10 µM. A minute amount of
the high molecular weight bands could still be present in the highly purified α-synuclein, and thus
negate the continued enhancement of the non-aggregated α-synuclein.
Next, with the highly purified α-synuclein, a detailed analysis was carried out which includes
the number of bilayer merger events at various α-synuclein concentrations (Figure 2.4A), the per-
centage of docked vesicles that merged (Figure 2.4B), the percentage of instant merging vesicles
vs. delayed merging vesicles (Figure 2.4C), and the kinetics of the time delay from docking until
bilayer merger (Figure 2.4D-F). Upon analysis of the number of bilayer merger events with and
without α-synuclein, it was apparent that increasing the amount of α-synuclein led to an increase
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Figure 2.4: Effect of α-synuclein on SNARE-dependent membrane fusion is mainly on docking
with little influence on the dynamics of bilayer merger. (A) Analysis of the bilayer merger dynamics
with twice purified α-synuclein. The number of merger events at various α-synuclein concentrations are
normalized with respect to events without α-synuclein. The dashed line represents the membrane merger
activity of SNAREs without α-synuclein. (B) Analysis of the bilayer merger efficiency of twice purified
α-synuclein. The efficiency is calculated as the number of merger events divided by the number of docking
events. (C) Instant merger vs. delayed merger. Instant merger events display lipid-diffusion in under 20
ms and delayed merger events are any that take longer than 20 msec. (D) Representative cumulative plot
of bilayer merger events with twice purified α-synuclein. The red line is the double exponential fit to the
data of merger events. (E) Plot of time constants for instant merger events. (F) Plot of time constants for
delayed merger events. The total of 1,247 merger events from 82 independent recording were included in the
fitting analysis.
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der to dissect the specific role of α-synuclein, the bilayer merger efficiency was investigated. The
merger efficiency (Figure 2.4B) shows that although there is a small decrease of the efficiency as
α-synuclein increases, it seems that the variation is overall within experimental errors. Thus, the
data shows that α-synuclein does not significantly affect the bilayer merger efficiency, revealing that
the increase in bilayer merger events with α-synuclein is mainly due to its dramatic enhancement
of vesicle docking.
Next, the time delay from docking until bilayer merger was analyzed (Figure 2.4C). For all
α-synuclein concentrations studied, nearly 70% of all bilayer mergers happen within the first 20
msec. after docking. The rest (30%) are spread over the remainder of the 30 sec. recording time. It
was not observed to have any significant changes on these results with α-synuclein. Further on, the
cumulative merger events were fit with a double exponential to find the first-order time constants
for both instant and delayed merger events (Figure 2.4D). The time constant for instant merger
varies between 2 and 5 msec. (Figure 2.4E) while the time constant for delayed merger varies
between 100 and 200 msec. (Figure 2.4F). Neither of the time constants changes significantly with
α-synuclein. Thus, the results show that α-synuclein has little effect on the time delay from docking
to bilayer merger.
2.3.3 Vesicles Are Not Clustered Upon Docking Onto the t-bilayer Surface in the
Presence of α-synuclein
Previously, Diao et al. (2013) showed with a single vesicle-to-vesicle assay that non-aggregated
α-synuclein induces vesicle clustering and argued that vesicle clustering is the cause of the en-
hancement of SNARE complex formation by α-synuclein. To examine if vesicles are clustered upon
docking on the supported bilayer, we measured the initial fluorescence intensities of all docking
events. An increase in the intensity would correlate to an increase in the number of vesicles in-
volved in a docking event. The intensity vs. population plot shows that the α-synuclein does not
shift or broaden the intensity distribution (Figure 2.5), indicating that α-synuclein-induced vesicle
























Figure 2.5: α-synuclein does not promote clustering of vesicles on the supported bilayer. Dis-
tribution of initial fluorescence intensities of individual docking events at various concentrations of twice
purified α-synuclein. The maximum population for each concentration is normalized to 1 for comparison.
The initial intensities of 2,194 docking events from 58 independent recordings are analyzed.
2.4 Discussion
There have been many attempts to elucidate the physiological role of normal, non-aggregated α-
synuclein. Studies with cultured neurons have observed that overexpression of α-synuclein impairs
neurotransmitter release (Larsen et al. (2006); Nemani et al. (2010); Lundblad et al. (2012); Phan
et al. (2017)). Knockout studies in mice showed no early phenotypes, but had earlier onset of
neurological issues (Chandra et al. (2004); Wu et al. (2010); Kokhan et al. (2012)). This leads
to the notion that α-synuclein has the potential to be toxic at excessive concentrations, but is
crucial at normal concentrations for as of yet unknown reasons. Multiple in vitro studies have
been performed with contradicting observations. Some groups observe that α-synuclein inhibits
SNARE-dependent membrane fusion (DeWitt and Rhoades (2013); Lai et al. (2014)), while others
observed an enhancement (Liu et al. (2004); Lou et al. (2017); Burré et al. (2014)). Previously, we
demonstrated in an in vitro single vesicle-vesicle fusion assay that α-synuclein has a very narrow
concentration window in which it enhances SNARE-dependent vesicle docking (Lou et al. (2017)).
Here, in order to better investigate α-synuclein’s role on SNARE-dependent membrane fusion, we
used a TIRF vesicle-to-supported bilayer merger assay. Unlike the vesicle-to-vesicle platform (Yoon










Figure 2.6: A proposed mechanistic model for enhancement and inhibition of SNARE-
dependent vesicle fusion by α-synuclein. The enhancement model involves monomeric α-synuclein
acting as a cross-bridge to facilitate vesicle docking to the phospholipid bilayer. α-synuclein has a N-terminal
membrane binding region that binds to the phospholipid bilayer and the C-terminal region that interacts
with VAMP2 (Lou et al. (2017)). The inhibition model involves oligomeric, multivalent α-synuclein inter-
acting and clustering VAMP2, thus preventing it from engaging in SNARE complex formation and vesicle
fusion.
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is a necessary improvement to avoid potential artifacts stemming from the α-synuclein’s preferential
binding to the curved membrane (Varkey et al. (2010); DeWitt and Rhoades (2013); Snead and
Eliezer (2014)). With this assay employing the highly pure protein, we show that α-synuclein
enhances SNARE-dependent vesicle docking even at excessive concentrations.
Although it may vary widely, the cellular concentration of α-synuclein is estimated to be roughly
5 µM (Chung et al. (2013); Seo et al. (2002)). Overexpression typically increases α-synuclein by
a factor of 2 to 3. Thus, our data shows that α-synuclein plays a positive role in vesicle-to-
bilayer merger under overexpression conditions. Why does overexpression of α-synuclein then
impair neurotransmitter release? We speculate that soluble aggregates of α-synuclein, although
small in quantity, interfere with the SNARE function. In fact, it is shown that soluble aggregates of
α-synuclein can inhibit SNARE-dependent membrane fusion effectively even at a 100 nM monomer
concentration (Choi et al. (2013)). Overexpression inevitably causes aggregation of α-synuclein over
time. The small increase of these high molecular weight bands is enough to negate any enhancement
by non-aggregated α-synuclein, which demonstrates their potency.
Our data shows that the promotive effect of α-synuclein on SNARE-dependent bilayer merger is
mainly through the enhancement of vesicle docking. Other than the number of vesicles docking, we
did not observe significant changes in the merger efficiency, the ratio of instant to delayed merger
events, or the kinetics of bilayer merger. However, it has been recently shown that α-synuclein
plays a role in accelerating fusion pore opening (Logan et al. (2017)). Because our assay uses a
lipid probe that reports the lipid dynamics, we are not able to test this mechanistic model on fusion
pore dynamics, warranting further investigation using the fluorescent content reporters.
Combining the present and previous work, two apparent tracks of the regulation of SNARE-
dependent membrane fusion by α-synuclein emerge (Figure 2.6). When α-synuclein is
non-aggregated, it plays a positive role in bilayer merger by promoting vesicle docking. Recently,
Lou et al. (2017) proposed a mechanistic model for this positive regulation, envisioning that α-
synuclein binds to VAMP2 using its unstructured C-terminus. It interacts simultaneously with
the target plasma membrane in trans using its amphipathic N-terminal region, whereby aiding the
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recruitment of synaptic vesicles to the plasma membrane. On the other hand, when aggregated,
the multivalent oligomeric species could bind to multiple VAMP2 on the vesicle, incapacitating
its ability to interact with t-SNARE on the plasma membrane (Choi et al. (2013)). As such, the
bilayer merger would be severely inhibited.
2.5 Conclusion
Overexpression of α-synuclein in vivo studies results in diminished neurotransmitter release in
cultured neurons. This supports the argument that in addition to the aggregates, excessive amount
of non-aggregated α-synuclein might be neurotoxic too. Our detailed analysis using an in vitro
single-vesicle bilayer merger assay shows that α-synuclein is beneficial for SNARE-dependent vesicle
fusion even at excessive concentrations, but the apparent toxicity of α-synuclein might be mainly
due to the presence of the aggregated species. We observed enhancement of SNARE-dependent
vesicle docking and bilayer merger, even in extreme concentrations of pure α-synuclein, with 13
fold enhancement at 10 µM α-synuclein. The vesicle-to-supported bilayer merger assay could help
reveal how SNARE regulators affect each step in SNARE-dependent membrane fusion and thereby
advance our understanding of how these regulators affect neurotransmission.
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2.6 Materials and Methods
2.6.1 Plasmid Constructs and Site-Directed Mutagenesis
DNA sequences encoding syntaxin-1A (amino acids 1-288 with three native cysteines replaced
by alanines), VAMP2 (amino acids 1-116 with C103 replaced by alanine), SNAP-25 (amino acids
1-206 with four native cysteines replaced by alanines), and α-synuclein (amino acids 1-140) were
inserted into a pGEX-KG vector as N-terminal glutathione S-transferase (GST) fusion proteins.
DNA sequences were confirmed by the Iowa State University DNA sequencing facility.
2.6.2 Protein Purification
All N-terminal GST recombinant neuronal SNARE proteins and α-synuclein were expressed in
Escherichia coli BL21 (DE3) cells. SNARE proteins were purified in the same manner as previously
detailed (Khounlo et al. (2017)).
The α-synuclein was grown at 37 ◦C in LB (Luria-Bertani) medium with 100 µg/mL ampicillin
until the absorbance at 600 nm reached 0.6-0.8. The cells were induced to express overnight by
adding IPTG (isopropyl β-d-thiogalactopyranoside, 0.3 mM) at 16 ◦C. Proteins were purified us-
ing glutathione-agarose chromatography. Cell pellets were resuspended in 15 mL of high salt PBS
(HSPBS) (497 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 , 1.8 mM KH2PO4, pH 7.4), with final
concentrations of 1 mM AEBSF [4-(2-aminoethyl)benzenesulfonyl fluoride], 2 mM DTT (dithiothre-
itol), and 20% N-lauroylsarcosine. Cells were lysed by homogenization and centrifuged at 25,000 xg
for 30 min at 4 ◦C. The supernatant was mixed with 1 ml of glutathione-agarose beads in HSPBS
by nutation at 4 ◦C for 2 h. After washing the protein with HSPBS, the protein was cleaved by
thrombin (30 U) at 4 ◦C overnight. The protein was eluted, concentrated to ∼t 1 mL, and then
loaded on to an AKTA FPLC with a GE Superdex Increase 200 10/300 column for size-exclusion
chromatography exchanging α-synuclein into PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
1.8 mM KH2PO4, pH 7.4). Samples from individual fractions were run on a 15% SDS-PAGE gel
to identify fractions that lacked high molecular weight bands (Figure 2.7). These fractions were









































































Figure 2.7: Two round gel filtration of α-synuclein.(A) Chromatogram from the 1st round of gel
filtration. After one round of gel filtration, α-synuclein elutes as two overlapping peaks between fractions
7-14. The UV absorbance value has been normalized with respect to the maximum peak intensity. (B) SDS-
PAGE gel after the 1st round of gel filtration. The fraction numbers indicated on the SDS-PAGE correspond
to the fractions shown in part (A). Fractions 7-10 display high molecular weight bands which correlates to
the first peak in the chromatogram. Fractions 11-14, indicated by arrows, were combined, concentrated, and
subjected to another round of gel filtration. (C) Chromatogram from the 2nd round of gel filtration. After
two rounds of gel filtration, α-synuclein elutes as a single peak between fractions 10-14. (D) SDS-PAGE of
the 2nd round of gel filtration. Fractions 12-14 display molecular weight bands consistent with α-synuclein
which correlates to the single peak in the chromatogram. A conservative approach was used and fractions
containing an arrow underneath were combined, concentrated and used for TIRF experiments.
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checked for any high molecular weight bands. Those without were combined, concentrated, had
glycerol added to a final concentration of 15%, and then stored at −80 ◦C (Figure 2.7). α-synuclein
was used within 2 weeks of purification. Aggregation into high molecular weight bands within this


















Figure 2.8: SDS-PAGE of purified α-synuclein
before and after storage at −80 ◦C. (A) SDS-
PAGE gel of α-synuclein immediately after two rounds
of gel filtration before storing at −80 ◦C. (B) SDS-
PAGE gel of the same α-synuclein after 2 weeks of
storage at −80 ◦C.
2.6.3 Western Blotting
The α-synuclein was run on a 12% SDS-
PAGE. SDS was rinsed from the gel by mi-
crowaving the gel in diH2O (deionized water)
for 40 sec. three times with each time ex-
changing the diH2O. An Invitrogen iBlotTM
two Dry Blotting System was used in transfer-
ring the protein to a PVDF membrane. The
membrane was then blocked overnight with 5%
(w/v) non-fat dry milk in TBST (20 mM Tris-
HCL, pH 7.4, 137 mM NaCl, 2.7 mM NaCl,
0.1% Tween-20) at 4 ◦C. The membrane was
rinsed with TBST twice, then incubated in 5%
(w/v) non-fat dry milk in TBST with 1 µg/mL
α-synuclein Monoclonal Antibody (Syn 211)
(Invitrogen #32-8100) for 2 hrs. at room temperature. Then, the membrane was rinsed three
times with TBST and incubated with 5% (w/v) non-fat dry milk in TBST with Goat Anti-Mouse
IgG (H + L)-HRP Conjugate (Bio-RAD #1706516) for 45 min. at room temperature. The mem-
brane was then washed with TBST three times and reacted with Pierce c© ECL Western Blotting




The t-bilayer was made using a mixture of POPC (1-palmitoyl-2-dioleoyl-sn-glycero-
3-phosphatidylcholine), DOPS (1,2-dioleoyl-sn-glycero-3-phosphatidylserine), PIP2 (phospha-
tidylinositol 4,5-bisphosphate from porcine brain), and PEG2000 (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) in chloroform at a molar ratio of
78:15:2:5. The v-lipid was made using a mixture of POPC, DOPS, cholesterol, and DiI (1, 1’-
Dioctadecyl-3, 3, 3’,3’-tetramethylindocarbocyanine perchlorate) in chloroform at a molar ratio
of 54:5:40:1. Both lipid mixtures were first dried under an air stream, then dried in a vacuum
overnight. The t-bilayer lipid was resuspended in HEPES (25 mM HEPES/KOH, 150 mM KCl, pH
7.4) + 1% OG (Octyl-β-Glucoside). The v-lipid was resuspended in HEPES and then underwent 10
flash freeze-thaw cycles moving from liquid nitrogen to boiling water. Protein-free large unilamellar
vesicles (∼100 nm in diameter) were prepared by extrusion through polycarbonate filters making
v-liposomes.
For the t-bilayer syntaxin-1A and SNAP-25 were mixed in a molar ratio of 1:1.5 and then the
mixture was left at room temperature for 0.5 h to form the t-binary complex before the reconsti-
tution. The t-bilayer lipid was added to the t-binary complex so that the lipid to t-binary complex
ratio was 2000:1. Then the liposome/protein mixture was diluted by adding three times the vol-
ume of the protein lipid mixture of HEPES. To generate functional v-vesicles, v-liposomes were
mixed with the VAMP2 at a lipid to VAMP2 ratio of 200:1. Then the liposome/protein mixture
was diluted by adding three times the volume of the protein lipid mixture using HEPES. Both
liposome/protein mixtures were dialyzed overnight at 4 ◦C in 2 L of HEPES containing Biobeads
SM-2 Resin.
2.6.5 Vesicle-to-Supported Bilayer Merger TIRF Assay
A quartz slide and glass cover slip were subjected to piranha cleaning by boiling them in a
1:1 mixture of concentrated sulfuric acid and 30% hydrogen peroxide for 15 min. The slides were
rinsed with diH2O and placed in a cleaning sonicator for 30 min. to remove residual acid. The
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slides were dried and prepared with double-sided tape and a cover slip to generate several separate
microfluidic chambers. The chambers were then filled with t-bilayer that was prepared from the
overnight dialysis. The t-bilayer was allowed to form on the quartz surface for 1 hr. at room
temperature. The excess liposomes/protein mixture was washed out with HEPES and replaced
with an indicated concentration of α-synuclein in HEPES. The α-synuclein was incubated with
t-bilayer for 1 hr. while heating at 37 ◦C.
The quartz slide with the microfluidic chambers was then placed on the imaging stand of the
microscope, which regulated the temperature of the slide to 37 ◦C. Imaging oil was put on the
prism of a prism-type total internal reflection fluorescence (TIRF) microscope, and then the prism
was lowered onto the quartz slide. The incident angle of the exciting laser (532 nm) was adjusted
and real-time movie acquisition was initiated with an imaging area of ∼ 55 x ∼ 110 µm using
20 msec. time resolution. v-vesicles (from dialysis) were then gently injected with an indicated
concentration of α-synuclein into the microfluidic chamber. The injection pump was promptly
stopped after injection to prevent vesicle merger events from the flow effect (Figure 2.1A). We
collected 60 sec. movies for each microfluidic chamber and analyzed the final 30 sec. for docking
and merger events using our custom-built analysis software.
2.6.6 Data Analysis
Using our custom analysis software written in MATLAB c©2014 (b), we monitored the fluores-
cence intensity of DiI from the v-vesicles in order to determine docking and subsequent merger
events. Each recording was analyzed frame by frame based on both visual determination (Fig-
ure 2.1B) and fluorescence trace pattern analysis (Figure 2.2). Both criteria had to be met for
an event to be counted. All three events are initiated by both a vesicle becoming immobilized
on the surface and a sharp increase in the fluorescence. Instant merger events were then defined
as lipid diffusion happening on the very next frame as well as an immediate sharp fluorescence
decrease (Figure 2.2A). Delayed merger events were defined by lipid diffusion being observed sev-
eral frames after docking, with a secondary fluorescence spike upon lipid merger, followed by an
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immediate, sharp decrease (Figure 2.2B). Docking only events did not show lipid diffusion before
the fluorescence intensity faded gradually over time due to photo-bleaching (Figure 2.2C).
From the analysis, we counted individual immobilized v-vesicles, vesicles showing lipid merger,
and the delay time between docking and lipid merger within a movie clip. At least three independent
recordings were analyzed to obtain the statistical significance for each data set.
2.6.7 Exponential Curve Fitting
All membrane merging data was combined for each concentration of α-synuclein. The mem-
brane merging events were cumulatively plotted by binning events by the maximal delay. For
example, if the event was seen to fuse in a single frame, then it was binned in the 0-20 ms bin
and plotted as an event at 20 ms. MATLAB c© 2014 (b) curve fitting toolboxTM3.5 was used to
fit F (x) = A× (1 − e(−x)/B) + C × (1 − e(−x)/D) + E to the cumulative plot allowing A,B,C,D,
and E to be optimized using Non-linear Least Squares with Bisquare for robustness. Standard
deviations were calculated by taking all events for a concentration of α-synuclein and assigning
them randomly to a subgroup, fitting each subgroup, and comparing their best fitting parameters
to the global fit to the total data.
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T. H., and Rothman, J. E. (1998). SNAREpins: Minimal Machinery for Membrane Fusion. Cell,
92(6):759–772.
Wu, N., Joshi, P. R., Cepeda, C., Masliah, E., and Levine, M. S. (2010). Alpha-Synuclein overex-
pression in mice alters synaptic communication in the corticostriatal pathway. J. Neurosci. Res.,
88(8):1764–1776.
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3.1 Abstract
In the neuron, membrane fusion is the fundamental process in which neurotransmitters are
released to the synapse. It is believed that the SNARE complex is the minimal fusion machinery
that drives synaptic membrane fusion. Membrane fusion transits the hemifusion state and the
fusion pore prior to the complete merging of two membranes. However, it is hotly debated how
far the SNARE complexes can carry along the membrane fusion process. A recent report shows
that the SNARE complex is not even sufficiently potent to go beyond hemifusion (D’Agostino et
al. 2017, Nature, 551, 634-638B). But, others show that it has the capacity to sustain a small
fusion pore (Bao et al., 2018, Nature, 554, 260-263). Yet, it is unclear if SNARE complexes can
dilate the fusion pore. Here we use an in vitro single vesicle-to-supported bilayer fusion assay to
investigate fusion pore dilation by employing 10 kD dextran-rhodamine B (diameter about 6 nm)
as the fluorescent content probe. The results show that the SNARE complex alone is inefficient at
dilating and stabilizing the fusion pore. This results in pore contraction before full content release.
However, the addition of synaptotagmin-1 and Ca2+ promotes dilation of the fusion pore for nearly
all docked vesicles with a lower tendency of contraction than with SNAREs alone. Surprisingly,
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we observe a fluorescence signal consistent with deformation of vesicles to a flattened discus shape.
We propose a hypothetical mechanistic model by which SNAREs and particularly, synaptotagmin-
1/Ca2+ help dilate the fusion pore by stabilizing the membrane curvature.
3.2 Significance
Neurotransmitter release through the fusion pore is a fundamental step in neuronal communi-
cation. After release, the fusion pore must dilate for recycling of the vesicle through endocytosis.
However, the mechanism of the fusion pore dilation is elusive. We use an in vitro single vesicle
fusion assay to investigate fusion pore dilation by employing a large fluorescent content probe. We
discover that SNARE complex alone struggles to enlarge the pore before ultimately contracting.
However, a major Ca2+-sensor, synaptotagmin-1 helps dilation of the fusion pore for nearly all
vesicles in the presence Ca2+. We hypothesize that SNAREs assist in pore dilation by stabilizing
membrane curvature, and even more efficiently with synaptotagmin-1 and Ca2+.
3.3 Introduction
Communication between neurons, which underlies cognition, memory, and motor movement is
built upon neurotransmitter release at the synapse. In the neuron, cargo vesicles undergo membrane
fusion with the plasma membrane, which releases the neurotransmitters into the synaptic cleft.
This membrane fusion process transits through multiple distinct stages. Hemifusion, in which outer
leaflets of two bilayers are merged (Xu et al. (2005); Lu et al. (2005)), is followed by a small aqueous
fusion pore through which neurotransmitters are allowed to pass (Breckenridge and Almers (1988);
Han et al. (2004)). The small pore then dilates to a large pore that ultimately leads to a complete
merger of two membranes into a single bilayer (Chernomordik and Kozlov (2003)). Alternatively,
after release, the vesicle might disengage from the plasma membrane without complete fusion,
termed kiss-and-run (Alabi and Tsien (2013)). It is unknown what protein factors control the bias
between these two pathways.
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It is now established that the widely-conserved SNARE (soluble N-ethylmaleimide-sensitive
factor attachment protein receptor) complex is the minimal machinery for membrane fusion (Söllner
et al. (1993); Weber et al. (1998)). SNARE motifs from vesicle v -SNARE, VAMP2, and those from
target plasma membrane t-SNAREs, syntaxin-1A and SNAP-25, form a highly stable parallel
coiled-coil (Poirier et al. (1998); Sutton et al. (1998)). There is evidence that the SNARE complex
zippers from the membrane-distal region to the membrane-proximal region, funneling the folding
energy towards apposition and merger of two membranes (Gao et al. (2012); Min et al. (2013); Shin
et al. (2014)).
It has been long debated whether the SNARE complex is sufficiently potent to drive complete
membrane fusion. For yeast SNAREs, it has been recently shown that SNARE complexes are not
sufficient to push hemifusion forward to the small pore stages without the help of an auxiliary pro-
tein complex (D’Agostino et al. (2017)). In contrast, for neuronal SNAREs, there is overwhelming
evidence that SNARE complexes alone are capable of driving the opening of a fusion pore (Kyoung
et al. (2011); 2014; Wu et al. (2017); Bao et al. (2018); Diao et al. (2010)), although it is unclear
if SNARE complexes can support complete fusion pore dilation. Meanwhile, auxiliary proteins in-
cluding Ca2+-sensor synaptotagmin-1 (syt1), complexins, and α-synuclein are shown to play some
roles in the various stages of the fusion pore progression (Lai et al. (2013); Logan et al. (2017);
Lynch et al. (2008)).
Recently, in vitro electrophysiological methods monitoring fusion between a nanodisc and a cell
membrane (or a black lipid membrane) have scored impressive successes in revealing the dynamics
of the SNARE-induced fusion pore (Wu et al. (2017); Bao et al. (2018)). However, in this approach,
the nanodisc is likely to put a constraint on the dilation of the fusion pore and the complete merger
of two membranes will not be observed. Moreover, the experiment could not detect a potential
deformation of vesicles concurrent with fusion pore dilation.
In our work, we monitor the dynamics of the SNARE-induced fusion pore with a complimentary
single vesicle-to-supported bilayer fusion assay (Kim and Shin (2017); Kiessling et al. (2017); Liu
et al. (2005)). By using a large dextran probe of 6 nm in diameter (Arrio-Dupont et al. (1996)),
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we are able to observe the transient opening and contraction of the large fusion pore in a small
subset of vesicles. When we included syt1 and Ca2+, however, we observe a remarkable increase
in the number of vesicles that dilate to a large pore state without collapsing back to a small pore.
Surprisingly, we find that the fluorescence intensity increases concurrently with the release of the
vesicle content. This interesting observation is interpreted as the consequence of the deformation of
the vesicles from a globular shape to a discus shape. Based on this data, we propose a mechanism










Figure 3.1: Schematics of the single-vesicle-to-supported bilayer content release assay. (A)
Upon injection into the flow cell, v -vesicles begin to dock to the supported bilayer as v - and t-SNAREs
interact and begin zippering. This is visualized as a faint, immobilized spot. (B) As the v -vesicle is drawn
toward the supported bilayer through zippering of the SNARE complex, the spot increases in brightness.
(C) Once the SNARE complex is fully zippered it could form a small fusion pore, but there is no visible
2D diffusion because the fluorophore is larger than the pore. (D) As the fusion pore dilates past 6 nm, the
RB-dextran escapes the vesicle and is seen as a bright 2D diffusion from the centroid of the vesicle.
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3.4.1 Single vesicle-to-supported bilayer fusion assay is able to monitor an enlarged
fusion pore
To investigate the dynamics of the SNARE-induced fusion pore, we monitor the single vesicle-
to-supported bilayer fusion utilizing total internal reflection fluorescence microscopy (TIRFM) (Fig-
ure 3.1). The supported bilayer contains 5 mole% polyethylene glycol (PEG)-PE that creates a
PEG-pillared aqueous gap between the bilayer and the quartz support through which a fluorescent
reporter could diffuse. We use 10 kD dextran conjugated to rhodamine B (RB-dextran) as a flu-
orescent reporter for the fusion pore. The rationale for using large 10 kD RB-dextran is two-fold.
Firstly, the hydrodynamic radius of the molecules is estimated to be about 3 nm. Thus, unlike
small fluorescent probes, its 2D diffusion in the aqueous gap is predicted to be sufficiently slow to
be readily visible with TIRFM. Secondly, RB-dextran is allowed to escape from the vesicle when
the fusion pore opens larger than about 6 nm in diameter, enabling the detection of an enlarged
fusion pore.
The supported bilayer is prepared by spontaneous fusion of proteoliposomes, reconstituted with
t-SNAREs (lipid-to-protein ratio (L/P) = 2000), onto a clean, hydroxylated quartz surface in the
flow cell. The quality and the homogeneity of the supported bilayer are visually inspected under
a microscope by doping the proteoliposomes with 0.5 ppm of the lipid dye DiD (1,1’-Dioctadecyl-
3,3,3’,3’-Tetramethylindodicarbocyanine) prior to formation of the supported bilayer. Separately,
v -SNAREs are reconstituted into liposomes that encapsulate RB-dextran as internal content. They
are prepared by initially freeze-thawing lipids in the presence of 30 µM RB-dextran, and then by
extruding them through a 100 nm polycarbonate filter to generate liposomes. The v -SNARE,
VAMP2 (L/P = 200), is then reconstituted into the 100 nm liposome pool to make v -vesicles.
The sample to be injected into the flow cell has 250 nM of v -vesicles (total lipid concentration)
encapsulating 30 µM of RB-dextran. The sample contains 3.75 nM of RB-dextran in the bulk
solution which does not affect our measurements.
To monitor the enlarged fusion pore, the v -vesicles are injected into the flow cell containing
the pre-formed supported bilayer. The SNARE complexes begin assembly when the v -SNAREs
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on the v -vesicles interact with the t-SNAREs on the supported bilayer. The formation of the
SNARE complexes mediates the vesicle docking and fusion. When a v -vesicle docks to the bilayer,
a fluorescent spot appears on the imaging surface (Figure 3.1 & Figure 3.2A). Subsequently, if a
fusion pore greater than 6 nm in diameter is induced, we observe that the spot emits 2D diffusion
of RB-dextran (large content release).
3.4.2 SNAREs are capable of driving fusion pore dilation past 6 nm
Out of total 725 docking events analyzed, we observe large content release for 274 events (38%)
(Figure 3.2B). However, content release is not detected for majority of docked vesicles (62%). Thus,
the results show that SNAREs are capable of mediating pore expansion for only a subset of docked
vesicles. For the content release events, the duration of the release varies greatly ranging from 0.02
s to 3.60 s with the average duration of the release being 1.11 s (Figure 3.2C). It is of note that for
a small percentage of the docked vesicles (4%), we observe 2 or more discrete release events from
a single docked vesicle.
To confirm that content release is SNARE-dependent, individual SNARE proteins are omitted
or replaced in separate assays (Figure 3.2D). The v -SNARE dependence is tested using v -vesicles
without VAMP2. When these vesicles are flowed over the bilayer, there are virtually no content
release events. The t-SNARE dependence is evaluated using a SNAP-25 truncation mutant, SNAP-
25E, consistent with the product of Botulinum toxin E cleavage. For SNAP-25E, 26 residues
from the C-terminal SNARE motif have been removed, which has been shown to impair vesicle
docking. Again, there are virtually no content release events. In both controls, there are false
events displaying vesicles that transiently dwell on the bilayer, without content release, followed by
disengagement from the membrane (Figure 3.2E). Events with such a fluorescent trace pattern are
excluded in the analysis.
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Large pore  l ife-time (s)
Figure 3.2: Single-vesicle-to-supported bilayer fusion assay detects large pore formation
through 2D diffusion. (A) Representative raw images of a large pore release event. A content laden
vesicle docks to the supported bilayer as a bright spot at the 20 ms time frame (red). As the vesicle forms
a large fusion pore (greater than 6 nm), it releases its content visualized by 2D diffusion of fluorophores in
frames 40 - 80 ms (green). The 2D diffusion stops between 80 - 100 ms time frames. After this, no further
2D diffusion is observed. Instead, the spot fades out slowly (blue), indicating a slow leakage of dyes until all
the content is released at frame 240 ms (black). Raw movie of a large pore content release event is shown
in Movie S1. (B) As the v -vesicle is drawn toward the supported bilayer through zippering of the SNARE
complex, the spot increases in brightness. (C) Once the SNARE complex is fully zippered it could form a
small fusion pore, but there is no visible 2D diffusion because the fluorophore is larger than the pore. (D)
As the fusion pore dilates past 6 nm, the RB-dextran escapes the vesicle and is seen as a bright 2D diffusion




































































Figure 3.3: Content release is concurrent with an initial increase of the fluorescence intensity.
(A) Representative fluorescence trace of content release. The vesicle docks to the supported bilayer causing
an initial spike in fluorescence (red). The vesicle begins content release on the incline and subsequent sharp
decrease in fluorescence (green). Next, a steady decrease in fluorescence without 2D diffusion is observed
(blue). The vesicle eventually releases the entire content reducing the fluorescence back to baseline (black).
The ** indicates the maximum fluorescence during the large pore release and the * indicates the fluorescence
at the end of the large pore release. These intensities are used to calculate the amount of large pore release as
described in the materials and methods and are presented in (D). (B) Hypothetical schematic of membrane
deformation. This large structural change in the vesicle geometry would bring the internal fluorophores
closer to the surface, and thus towards the evanescent wave. SNARE complex illustrations are removed for
clarity. (C) Representative fluorescence trace of slow content release without 2D diffusion. The vesicle docks
to the supported bilayer and gradually releases content through a putative small fusion pore. The same color
scheme was used as in (A). The fluorescence intensity at the maximum of the small pore release event is
significantly lower than that of the large pore release event. (D) Distribution of content release. 273 release
events from 14 independent measurements were analyzed.
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3.4.3 Large content release is concurrent with the early increase of the fluorescence
intensity
To monitor the dynamics of the large content release, we follow the changes in the fluorescence
intensity of a single fusing vesicle in real time. We expected that the fluorescence intensity would
decrease as RB-dextran escaped and diffused away from the vesicle. Surprisingly, however, we ob-
serve that the fluorescence intensity increases during the initial period of content release, but shows
a decrease in the later period prior to visual cessation of 2D diffusion (green trace, Figure 3.3A).
Since the entrapped dye concentration (30 µM) is much lower than the critical concentration for
self-dequenching, we rule out the possibility of fluorescence self-dequenching due to the dilution as
the consequence of the release (Figure 3.6).
A plausible scenario for the initial increase of the fluorescence intensity is that the internal
content of the vesicle moves further into the evanescent wave. This may be attained by flattening
the vesicle to a discus shape during fusion pore dilation (Figure 3.3B).
3.4.4 Incomplete release of a large content shows contraction of SNARE-induced
large fusion pore
From the analysis of our data, we find that a majority of docked vesicles (62%) do not display
2D diffusion release of RB-dextran through a large fusion pore. Instead, these vesicles show a
steady, but slow decrease of the fluorescence intensity (Figure 3.3C), most likely indicating the
slow leakage of the content via a small fusion pore. In fact, Chapman and coworkers have recently
shown that SNARE complexes alone can sustain prolonged opening of a small fusion pore (Bao
et al. (2018)).
Furthermore, for the docked vesicles that did display content release (38%), the duration of the
release event is not sufficiently long to eject all the content, leaving significant residual amounts of
RB-dextran in the vesicle. The average amount of content released for the vesicles is 63% (Fig-
ure 3.3D). Astoundingly, only a small population of all the docked vesicles (6%) show complete
release of their content. The results show that although for some vesicles the fusion pore is tran-
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siently enlarged, most pores contracts back to a small pore without proceeding to full fusion. Thus,
our results show that SNAREs alone are not sufficient to fully expand the fusion pore to complete
membrane fusion.
3.4.5 Synaptotagmin-1 and Ca2+ are essential to achieve complete membrane fusion
Synaptotagmin-1 (syt1) is an auxiliary protein that renders the tight regulation of exocytosis
by Ca2+ (Chapman (2008); Fernández-Chacón et al. (2001)). Also, it has been proposed that syt1
plays a role in promotion of fusion pore dilation (Lai et al. (2013); Lynch et al. (2008)). In order
to comprehend how syt1 helps fusion pore dilation, we reconstitute syt1 together with v -SNARE,
VAMP2, into the v -vesicles (syt1-v -vesicles). The syt1-v -vesicles are premixed with 500 µM Ca2+
prior to injection into the flow cell.
In stark contrast to SNAREs alone, vesicles with syt1 and Ca2+ mostly have a single release
that is very rapid releasing the large majority of their content (Figure 3.4A). For the syt1-v -
vesicles, 97% of docked vesicles show content release, indicating that the majority of docked vesicles
shift towards opening large fusion pores (Figure 3.4B). In addition, the introduction of syt1 and
Ca2+ compared to SNAREs alone reduces the duration of content release (220 ms vs. 1110 ms,
respectively) (Figure 3.4C) and increases the amount of content release (81% vs. 24%, respectively)
(Figure 3.4D). The results suggest that the diameter of fusion pore in the presence of syt1 and Ca2+
is much larger than that for SNAREs alone. With syt1 and Ca2+, more internal content is released
in shorter period of time (Figure 3.4E). Altogether, it appears that syt1 and Ca2+ compared to
SNAREs alone drive 10-fold more vesicles (65% vs 6%, respectively) to fully release their content
(90-100%). Thus, our results show that syt1 and Ca2+ play an essential role in fully dilating the
fusion pore to complete membrane fusion.
For controls, in the absence of Ca2+, syt1-v -vesicles display content release in 62% of the docked
vesicles, which is an increase over SNAREs alone, but it is not as effective as in the presence of
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Figure 3.4: Synaptotagmin-1 (syt1) and Ca2+ enhance the efficiency of large pore content
release. (A) Representative fluorescence traces contrasting content release with SNAREs alone and with
the addition of syt1 and Ca2+. (B) Distribution of docked vesicles vs. number of content release events.
(C) Life-time of large fusion pores. In comparison to SNAREs alone, addition of syt1 and Ca2+ greatly
reduce the duration and tighten the distribution of large pore content release (from 1110 ± 1450 ms to 220
± 190 ms, respectively). In the absence of Ca2+, the duration is 530 ± 450 ms. (D) Distribution of content
release. In comparison to SNAREs alone, addition of syt1 and Ca2+ increased the amount of content release
(from 25 ± 34% to 83 ± 17%). In the absence of Ca2+, it is 54 ± 36%. The amount of large pore release
is calculated the same as in Figure 3.3D. (E) Scatter plot of content release amount vs. release duration.
In total, we analyzed 725 release events from 14 independent measurements for SNAREs alone, 484 release
events from 20 independent measurements for syt-1 with Ca2+, and 437 release events from 6 independent
measurements for syt1 alone. The large striped area at the intersection of the axes represents 451 spots (62%
of the SNARE alone events) that have no content release.
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that in the absence of Ca2+, syt1-v -vesicles do not generate a large pore as consistently as in the
presence of Ca2+.
3.5 Discussion
The SNARE complex has long been believed to be the minimal fusion machinery necessary
for fusing the neurotransmitter-laden vesicle with the presynaptic membrane (Weber et al. (1998);
Jahn and Scheller (2006)). While SNARE complexes have been shown to be sufficient to form small
fusion pores (Wu et al. (2017); Bao et al. (2018)), it is unclear how far they can carry the vesicle
through the fusion process. Since the SNARE complex is expected to be fully formed prior to pore
dilation, it may not be able to provide the necessary force for the energy-demanding step of pore
dilation (Chernomordik and Kozlov (2008)). In our work, we explore how far SNARE complexes
can advance the fusion process and characterize the role that syt1 and Ca2+ play in dilating the
fusion pore.
With the single vesicle-to-supported bilayer fusion assay employing 10 kD RB-dextran as the
fluorescent content probe, we show that SNARE complexes alone can expand the fusion pore larger
than 6 nm in diameter for a subset of docked vesicles (38%). However, the majority of the docked
vesicles (62%) are not able to reach a pore size sufficiently large to allow release of 6 nm-diameter
RB-dextran. Interestingly, we find that the SNARE-induced large pore is transient. After some
release, it collapses back to a very slow release state, which is most likely a small pore stage. Such
incomplete dilation leaves residual RB-dextran in the vesicle. This suggests that although SNARE
complexes can generate a transient large fusion pore, they are not fully sufficient to drive the
complete dilation of the fusion pore.
An unexpected, but important observation is the increase in fluorescence during the initial
release phase despite the internal fluorophore concentration not being within the self-quenching
range. A probable explanation for this is that the vesicle is being drawn further down toward
the bilayer. TIRFM exploits an evanescent wave to illuminate only 200 nm into the solution.
This wave field exponentially decays away from the surface. So, decreasing the distance from
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VAMP2 SNAP-25 Synaptotagmin-1 Ca2+Syntaxin-1A
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Figure 3.5: Hypothetical model of membrane remodeling into a discus form. (A) SNAREs alone
have the ability to open a small fusion pore and occasionally dilate larger prior to contraction. A transient
large pore may be possible through the stabilization of the membrane curvature at the pore rim by peripheral
SNARE complexes. The peripheral SNARE complexes may be half-zippered and can be easily dissociated.
(B) Trans-binding of syt1 to both membranes stabilizes the membrane curvature at the rim of the fusion
pore. Two possible scenarios are where (1) the C2A and C2B domains of syt1 work together to stabilize the
fusion pore curvature or (2) the C2B alone bridges the two membranes stabilizing the fusion pore curvature.
We speculate that the syt1 interaction with membranes is stronger than that of the half-zippered SNARE
complex.
the surface could drastically increase the fluorescence. The docked vesicle is already connected
to the bilayer via fusion pore and there may be no room to draw down the vesicle further to the
surface while maintaining the globular shape. On the other hand, the vesicle could be deformed to a
hypothetical discus shape so as to bring the internal content closer to the surface. We speculate that
peripheral SNARE complexes could play a role in flattening the vesicle (Figure 3.5A). Additional
SNARE complexes formed away from the fusion site would pull and flatten the vesicle to become
ellipsoidal and draw the fluorescent content further into the evanescent field. These peripheral
SNARE complexes could be partially zippered and not sufficiently organized to cause membrane
fusion. However, they are able to stabilize the membrane curvature at the rim of the fusion pore,
but could be easily be broken apart, terminating their effect on stabilizing the membrane curvature.
Our results demonstrate that syt1 and Ca2+ dramatically enhances fusion pore dilation. In the
presence of syt1 and Ca2+, nearly all the docked vesicles (97%) progressed to form large pores
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which is in stark contrast to SNAREs alone (38%). Moreover, more internal content is released in
shorter period of time, indicating that larger pores are developed. In fact, with syt1 and Ca2+,
10-fold more vesicles than SNARE alone (65% vs 6%, respectively) have 90-100% of RB-dextran
released, suggesting that many fusion pores are dilated to complete fusion. Here again, the release
is accompanied with the increase in the fluorescence intensity. We could envision that the same
mechanism works for SNAREs alone and in the presence of syt1 and Ca2+ (Figure 3.5B). It has
been previously shown that the C2A domain has the preferential affinity to the vesicle while C2B
binds to the plasma membrane (Nyenhuis et al. (2019)). Such a selective binding in the periphery
would bring about the deformation of the vesicles into a discus shape. Alternatively, the C2B
domain could bridge two membranes, which would also contribute to the deformation of the vesicle
(Xue et al. (2008)). The strong interaction of syt1 and Ca2+ with a membrane could counter the
disassembly of weak, partially zippered SNARE complexes in the periphery. In reality, synaptic
vesicles are smaller than the proteoliposomes used in our study. Thus, one may not be able to
observe the global deformation of the vesicle shape during the fusion pore expansion in vivo as we
have seen in our in vitro work. However, we propose that the peripheral trans-SNARE complexes
and trans-bound syt1 would contribute to the stabilization of the membrane curvature of the fusion
pore in a similar fashion, thereby promoting the fusion pore dilation.
In summary, elucidating the mechanism by which SNARE complexes and syt1 and Ca2+ drive
membrane fusion is of great general interest. In this work, using the in vitro single vesicle-to-
supported bilayer fusion assay employing 10 kD RB-dextran, we demonstrate that SNARE com-
plexes could drive the enlargement of the fusion pore greater than 6 nm in diameter, but it collapses
without progressing toward full dilation. However, in the presence of syt1 and Ca2+, more vesi-
cles reach complete fusion quickly. We propose the discus model for fusion pore dilation, wherein
SNARE complexes or syt1/Ca2+ bridge two membranes to induce deformation of the vesicle that
stabilizes the curvature in the fusion pore. This model could be tested by using mutations that




3.6.1 Plasma Constructs and Site-Directed Mutagenesis
DNA sequences encoding SNAP-25 (amino acids 1-206), SNAP-25E (amino acids 1-180),
syntaxin-1A (amino acids 1-288), and VAMP2 (1-116) are inserted into a pGEX-KG vector as
N-terminal glutathione S-transferase (GST) fusion proteins. The DNA sequence encoding
synaptotagmin-1 (amino acids 50-421) is inserted into a pET-28b vector as C-terminal His-tagged
protein. Native cysteines are replaced by alanines for all the sequences. Synaptotagmin-1 also
contains a C82S mutation. DNA sequences are confirmed by the Iowa State University DNA
Sequencing Facility.
3.6.2 Protein Expression and Purification
N-terminal GST fusion proteins (SNAP-25, SNAP-25 E, syntaxin-1A, and VAMP2) are ex-
pressed and purified in the same manner as previously detailed (Hawk et al. (2019); Khounlo
et al. (2017)). C-terminal His-tagged synaptogamin-1 is expressed in Escherichia coli BL21 (DE3)
competent cells. Cells are grown at 3737 ◦C in LB medium with kanamycin (50 µg/mL) until
the absorbance at 600 nm reaches 0.6-0.8, and induced (through addition of IPTG (isopropyl β-D-
thiogalactopyranoside, 0.3 mM final concentration) to express overnight at 16 ◦C. Cells are pelleted
and resuspended in a HEPES wash solution (25 mM HEPES, 400 mM KCl, 0.2% Triton X-100, 20
mM imidazole at pH 7.4) with final concentrations of 1 mM AEBSF [4-(2-aminoethyl)
benzenesulfonyl fluoride] and 4 mM DTT (dithiothreitol). Cells are lysed by homogenization and
centrifuged to separate the supernatant from the pellet. The supernatant is collected and mixed
with Ni-NTA resin in a batch purification method. After incubation the protein is purified by wash-
ing the resin with HEPES wash solution. The protein is then eluted with the 25 mM HEPES, 400
mM KCl, 0.08% Octyl-beta-glucoside (β-OG), 400 mM imidazole at pH 7.4. All purified proteins
samples are verified for purity using a SDS-PAGE.
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3.6.3 Membrane Synthesis
The lipids used to form the supported-bilayer (t-lipids) are made using a mixture of POPC (1-
palmitoyl-2-dioleoyl-sn-glycero-3-phosphatidylcholine), DOPS (1,2-dioleoyl-sn-glycero-3-phospha-
tidylserine), PIP2 (phosphatidylinositol 4,5-bisphosphate), and PEG2000-PE (1,2-dipalmitoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) in chloroform at a molar
ratio of 78:15:2:5. The lipid mixture is first dried under an air stream, then dried further in a
vacuum overnight. The t-lipids are resuspended in HEPES-OG (25 mM HEPES/KOH, 150 mM
KCl, 1% β-OG, pH 7.4).
The lipids used to form liposome for v -SNARE VAMP2 reconstitution (v -lipids) are made using
a mixture of POPC, DOPS, and cholesterol in chloroform at a molar ratio of 54:5:40. The v -lipids
are resuspended in HEPES with 30 µM Rhodamine B conjugated to 10 kD dextran before 10 flash
freeze-thaw cycles, moving between liquid nitrogen and boiling water. Unilamellar vesicles were
prepared by extrusion through 100 nm diameter polycarbonate filters to make v -liposomes.
3.6.4 SNARE Reconstitution
For the supported bilayer, syntaxin-1A and SNAP-25 are premixed in a molar ratio of 1:1.5,
and the mixture incubated at room temperature to form the t-SNARE complex. The t-lipids are
added to the t-SNARE complex at a lipid:syntaxin-1A ratio of 2000:1. The mixture is diluted
3-fold using HEPES to reduce detergent concentration and insert the t-SNARE complex into the
t-lipids. The mixture is then dialyzed overnight at 4 ◦C in 2L of HEPES containing Bio-BeadsTM
SM-2 Resin to remove all detergent.
For content vesicles, v -liposomes are mixed with VAMP2 alone or along with synaptotagmin-1
(1:1 SNARE: syt1 ratio) at a lipid-to-protein ratio of 200:1. The mixture is diluted and dialyzed
in the same manner as described above while ensuring that concentration of RB-10 kD dextran
remaines constant at 30 µM.
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3.6.5 Vesicle-to-Supported Bilayer Fusion Release Assay
The assay is performed as previously detailed (Hawk et al. (2019)). When imaging SNARE
only conditions, post-dialysis v -vesicles, containing VAMP2 alone are injected into the flow cell at
a rate of 50 µL/min, stopping the pump promptly following first observation of events to prevent
vesicle merger being impacted by flow effect. When imaging synaptotagmin-1 conditions, post-
dialysis syt1-v -vesicles containing VAMP2 and synaptotagmin-1 are pre-mixed with 500 µM Ca2+
prior to injection into the flow cell. Sixty second movies are collected using 20 ms frame intervals
and analyzed for content release events using custom-built analysis software.
3.6.6 Data Analysis
Fluorescence of RB-dextran from the content vesicles is monitored to determine content release
events using in-house MATLAB c© 2014 (b) analysis software. Each recording is analyzed frame by


















Figure 3.6: Concentration dependence of RB-
dextran self-quenching. RB-dextran fluorescence
reaches its maximum fluorescence around 37 µM.
Large pore content release is indicated when
a vesicle immobilized and fused on the surface
displays 2D diffusion of the fluorophore. The
corresponding fluorescence trace shows a large
spike in fluorescence followed by a sharp de-
crease within less than 2 seconds. Events that
do not form a large pore are indicated when a
vesicle immobilized on the bilayer displays no
visible 2D diffusion of the fluorophore. The
corresponding fluorescence trace shows a large
spike in fluorescence followed by a slow decay
to baseline over several seconds. False events are when a vesicle became immobilized on the surface
and disengaged after several seconds without any visible release. The fluorescence trace of a false
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event contained a sharp increase in fluorescence, do not decay over several seconds during a plateau
period, and then sharply decline to baseline. False events were not included in the data analysis.
This lack of fluorescence decay also indicates that photobleaching is not observable in the time
scales we are measuring.
The selected traces corresponding to content release events are background corrected by fitting
the minimum baseline for all traces from a single recording with a polynomial and then subtracting
the polynomial from all the traces. The number of content release events are manually counted. The
amount of content release for individual vesicles is quantified by dividing the difference between the
fluorescence value at the maximum (max)** and end of large pore release (min)* by the maximum
(max) giving the formula (max - min) / max during the period of the green trace in Figure 3.3A.
The duration of release was quantified as the time from the beginning to end of large pore content
release.
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D’Agostino, M., Risselada, H. J., Lürick, A., Ungermann, C., and Mayer, A. (2017). A tethering
complex drives the terminal stage of SNARE-dependent membrane fusion. Nature, 551:634–638.
Diao, J., Su, Z., Ishitsuka, Y., Lu, B., Lee, K. S., Lai, Y., Shin, Y. K., and Ha, T. (2010). A
single-vesicle content mixing assay for SNARE-mediated membrane fusion. Nat. Commun., 1(5).
Fernández-Chacón, R., Königstorfer, A., Gerber, S. H., Garćıa, J., Matos, M. F., Stevens, C. F.,
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T. H., and Rothman, J. E. (1998). SNAREpins: Minimal Machinery for Membrane Fusion. Cell,
92(6):759–772.
Wu, Z., Bello, O. D., Thiyagarajan, S., Auclair, S. M., Vennekate, W., Krishnakumar, S. S.,
O’Shaughnessy, B., and Karatekin, E. (2017). Dilation of fusion pores by crowding of SNARE
proteins. eLife, 6.
Xu, Y., Zhang, F., Su, Z., McNew, J. A., and Shin, Y. K. (2005). Hemifusion in SNARE-mediated
membrane fusion. Nat. Struct. Mol. Biol., 12(5):417–422.
Xue, M., Ma, C., Craig, T. K., Rosenmund, C., and Rizo, J. (2008). The Janus-faced nature of the
C2B domain is fundamental for synaptotagmin-1 function. Nat. Struct. Mol. Biol., 15(11):1160–
1168.
53
CHAPTER 4. SPECIFIC INTERACTION BETWEEN α-SYNUCLEIN AND
v-SNARE VAMP2 STABILIZE FUSION PORE DILATION AND CONTENT
EJECTION
As drafted for submission
Brenden Hawk1, Ryan Khounlo1, Julien Roche, and Yeon-Kyun Shin
1: Co-first authors
4.1 Abstract
Since it was discovered to be the major component of Lewy bodies, α-synuclein has been the
focus of research endeavoring to eliminate and cure synucleinopathies. These are a devastating
class of diseases that deprive people of control over their own minds and bodies. Progress has
been made in understanding how α-synuclein aggregates and becomes toxic, but with limited
progress in disease prevention or alleviation. Now the focus has shifted to identifying α-synuclein’s
natural physiological role. It has been implicated in regulating pools of vesicles ready for release
and increasing the stability of vesicles on the presynaptic membrane to promote the formation of
more secure SNARE complexes. Very recently it has been proposed that α-synuclein may also
function as a pore dilator. Here we demonstrate that α-synuclein enhances the amount of content
vesicles release by serving as a molecular tether between the incoming vesicle and the presynaptic
membrane.
4.2 Introduction
Aggregation of proteins is widely recognized as the hallmark of Alzheimers and Parkinsons
disease (Lee and Trojanowski (2006); Spillantini et al. (1998); Iwai et al. (1995)). The aggregates
inhibit the system responsible for neurotransmitter release and leads to cellular death. While
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Figure 4.1: A diagram of SNARE-mediated membrane fusion. The v -SNARE, VAMP2 located
on the incoming vesicle initiates binding to the t-SNARE Syntaxin-1A and SNAP25 pair on the plasma
membrane. This holds the vesicle in the docking stage. The v - and t- SNARE then start to form a coiled-
coil drawing the vesicle closer to the plasma membrane until the outer leaflets of the two membranes merge.
This is the hemi-fusion state. The completion of the SNARE complexs coiled-coil drives the merger of the
inner leaflets on the membranes and form the small fusion pore. This pore then expands through the large
pore state and ends with the vesicle membrane having fully merged with the plasma membrane.
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the mechanisms of toxicity for these aggregates has been profusely studied, little is known about
the natural, healthy role of these proteins. That knowledge is essential if we want to assist in
maintaining their optimal function.
Currently, progress is being made on this front with the Parkinsons associated protein α-
synuclein. Burre et al. identified that α-synuclein possibly prolongs mental health by interacting
with the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex
(Burré et al. (2010)). The SNARE complex is the molecular machinery that fuses a vesicle to the
outer membrane of neurons causing a synapse (Figure 4.1) (Brunger (2005)). It has two halves: one
on the vesicle (v-SNARE) comprised of VAMP2 and another on the target membrane (t-SNARE)
consisting of syntaxin-1A and SNAP-25. Membrane fusion is initiated by the vesicle being docked
to the presynaptic membrane (Figure 4.1). As the SNARE complex folds into a coiled-coil it draws
vesicles closer to the outer membrane until they fuse forming a fusion pore to release neurotrans-
mitter.
Lou et al. (2017) discovered that α-synuclein has a concentration dependent enhancement of the
SNARE complex helping to unify previously conflicting findings that it is either toxic or beneficial.
Hawk et al. (2019) then demonstrated that α-synuclein enhances SNARE activity at the stage of
docking vesicles to the presynaptic membrane, but does not alter subsequent steps in membrane
fusion. They propose that α-synuclein stabilizes the vesicle to the membrane allowing for better
formation of SNARE complexes. Logan et al. (2017) observed a similar enhancement of SNARE
activity measured by the release of fluorescent protein from cells. Their conclusion was that α-
synuclein was facilitating this increase by functioning as a fusion pore dilator. These hypotheses
seems to be in contradiction, but that may not be so. None of the assays employed in these
discoveries were able to directly observe the formation and dilation of the fusion pore. This has
been a significant challenge for the field and there has not previously been a well-defined biochemical
assay for quantifying this process.
Here we describe a single vesicle-to-supported bilayer fusion assay that we developed to specif-
ically monitor the formation of fusion pores and quantify their characteristics as they dilate. We
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employ total internal reflection fluorescent microscopy (TIRFM) in conjunction with a fluorophore
congregated to 10 kDa dextran. The size allows for both ease of tracking with TIRFM and enables
us to observe individual fusion pores as they expand to 6 nm in diameter and beyond. We find
that while the SNARE complex alone is inefficient at dilating fusion pores, α-synuclein enables
this to be overcome by promoting multiple releases of content per vesicle. This allows for a drastic
increase in the amount of cargo released. Further investigation reveals that α-synuclein facilitates
this increased activity without altering the characteristic of the fusion pore generated by SNAREs
alone. We hypothesize that α-synuclein does this by acting as a molecular tether increasing the
number of anchors to the plasma membrane. This could both increase the stability of the vesicle
near the membrane and increase the surface area available for fusion pores to form.
4.3 Results
4.3.1 Monitoring fusion pore dilation with a single vesicle-to-supported bilayer fusion
assay
To understand the effect of α-synuclein on fusion pore dilation, we first needed to characterize
the fusion pore generated by the SNARE complex alone. A supported bilayer is generated by the
spontaneous fusion of proteoliposomes containing 5% PE-(PEG 2000) and t-SNAREs in a 1:2000
protein to lipid ratio. The PEG provides an aqueous gap for the 2D diffusion of dye as it is ejected
by the vesicles. Additionally, the proteoliposomes are doped with 0.5 ppm lipid dye DiD (1,1’-
Dioctadecyl-3,3,3’,3’-Tetramethylindodicarbocyanine) in order to determine the mobility of the
bilayer. Independently, v -vesicles are prepared by freeze/thawing lipids in 30 µM 10 kD dextran
conjugated to rhodamine B (RB-dextran) and extruded through a 100 nm polycarbonate filter to
generate liposomes. The v -SNARE VAMP2 is then reconstituted into these 100 nm liposomes. The
final v -vesicles have 30 µM RB-dextran as cargo and VAMP2 in a protein to lipid ratio of 1:200.
The v -vesicles are injected into the flow cell containing the preformed supported bilayer and
visualized with TIRFM. When a vesicle draws near the supported-bilayer and the SNARE complex
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Figure 4.2: Schematic of pore dynamics assay using single-vesicle-to-supported bilayer content
release. Vesicles are injected into the TIRf flow cell. (A) The v -SNAREs bind to the t-SNAREs and start to
form a coiled-coil. (B) As the coiled-coil progresses, the vesicle is drawn to the bilayer. (C) The completion
of the coiled-coil causes a small fusion pore to form. No content is yet released because it is larger than the
fusion pore. (D) As the pore dilates to a large pore the content is released. (E) This process is recorded in
real-time. Analysis of the recording and (F) the trace of fluorescent intensity allows for the differentiation of
docking (red), content release (green), small pore leakage (blue), ending in a return to baseline (black). (G)
This process is SNARE complex dependent with abrogation of all release events upon removal of v -SNARE
VAMP2 or truncation of the t-SNARE SNAP25.
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SNARE complex creates a fusion pore (Figure 4.2C). As the fusion pore dilates past 6 nm the RB-
dextran starts to escape and is diffused away from the vesicle (Figure 4.2D). This visual progression
is captured as a fluorescent trace (Figure 4.2E and F). The image with the red boarder and the red
region of the fluorescent intensity trace correspond to when the vesicle docks to the bilayer. The
image with the green boarder and the green section of the trace is when the vesicle has formed a
fusion pore greater than 6 nm and is visibly seen releasing content. The blue sections correspond
to when the fusion pore has contracted and can no longer be visibly seen releasing content, but is
still slowly leaking content through a small fusion pore. Once all the content has been evacuated
the fluorescent intensity returns to background levels and corresponds to the black bordered image

























Figure 4.3: A fluorescent inten-
sity trace from a vesicle with
multiple content releases. Arrows
in zoomed region indicate peaks of dis-
crete content release.
We confirmed the SNARE dependence of this process by
the removal or substitution of various components of the
SNARE complex (Figure 4.2G). The v -SNARE dependence is
tested by preparing v -vesicles without adding VAMP2. The t-
SNARE dependence is tested by substituting SNAP-25 with a
truncation consistent with the byproduct of Botulinum toxin E
cleavage. It is has had 26 residues removed from the c-terminal
SNARE motif and has been shown to impair vesicle docking.
In both cases there are virtually no release events.
4.3.2 α-synuclein promotes multiple discrete releases
of content per vesicle
We set out to ascertain if from a single vesicle perspective α-synuclein induced fusion pore
dilation. Single vesicles and discrete content release events were monitored to identify α-synuclein
effect on fusion pore dilation. It induced vesicles to have multiple distinct releases (Figure 4.3).
There was a large variety in both the number and sequence of releases (Figure 4.11). Vesicles
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range from having a single release event to five discrete releases with it being probable that there
could be more events that overlap and are not resolvable from other releases. There is also no
discernable pattern in the frequency in which the fusion pores form or dilate. Some vesicles have
obviously discrete releases (Figure 4.11 A and B), while others have releases with much more overlap
(Figure 4.11 C-F).
α-synuclein broadened the number of releases some vesicles had, but this would not have a
significant impact on content release as a whole unless it affected the majority of vesicles that dock.
To identify the percentage of docked vesicles that had an increased number of releases per vesicles,
each release was identified and all the releases per vesicle were summed. α-synuclein did indeed
affect the vast majority of the vesicles. It drastically increased the proportion of vesicles with
multiple releases from 38% for SNAREs alone to 99% in the presence of α-synuclein (Figure 4.4A).
Also, 54% of the docked vesicle in the presence of α-synuclein had multiple releases.
4.3.3 The induction of multiple releases per vesicle increased the amount of content
vesicles ejected
α-synuclein could have been increasing the number of releases per event by clustering vesi-
cles together as was observed by Diao et al. (2013). To identify if the increase in releases could
be attributed to multiple vesicles aggregating together, we plotted the correlation between the
maximum fluorescent intensity for an event against the number of discrete releases for that event
(Figure 4.4B). If the increase in fluorescence was correlated to the number of vesicle involved in
an event, a discrete increases in intensity should be observed with increased number of content
releases. This type of trend was not observed or any other trend that correlated to an increase
in content release events being dependent on the fluorescence of the event. This was confirmed
by the very large range of fluorescent intensities for each category creating very substantial and
overlapping standard deviations.
The increased amount of content releases event could also increase the amount of time vesicles
spent with large fusion pores open. To quantify this the duration of each release was measured and
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Figure 4.4: α-synuclein increases the number of content release events per vesicle leading to
an increase in the amount of content released from vesicles. (A) Number of content release events
per vesicle. This was measured as the number of discrete times dye is visibly released per vesicle. While the
majority of vesicles with the SNARE complex alone did not release content (62.2%), when α-synuclein was
added nearly all the vesicles did (99.6%). (B) There is no correlation between the maximum fluorescence
for a vesicle and the number of content release events it has. (C) The cumulative amount of time vesicles
spent with large fusion pores open. This was quantified by summing the duration of all large fusion pores
per vesicles. α-synuclein increased the time from 410 ± 550 ms with SNAREs alone to 1480 ± 710 ms with
the addition of α-synuclein. (D) The relative amount of content released from individual vesicles. This is
calculated by subtracting the fluorescence at the end of the last content release event from the maximum
fluorescence and then dividing by the maximum. The maximum was defined as the largest fluorescence
during content release. The majority of vesicles with SNAREs alone did not release any content (with an
average of 25% release). α-synuclein shifted the vesicles to release much more of their content (79%). A
total of 725 individual events across 19 independent recordings were analyzed for SNAREs alone and 681
events were analyzed across 33 independent recordings for the addition of α-synuclein.
61
then summed to give the cumulative time a fusion pore was open per vesicle. Docked vesicles in the
presence of α-synuclein spent nearly fivefold more time open increasing from 0.5 s with SNAREs
alone to 2.3 s with α-synuclein (Figure 4.4C).
The increased number of content release events would most likely also have affected the amount
of content ejected from each vesicle. To assess this the decrease in fluorescence intensity for each
vesicle was calculated by finding the relative difference between each events maximum fluorescent
intensity during a release event and the intensity at the end of the last release event. α-synuclein
increased the average amount of content released from 24% with just SNAREs to 77% with α-
synuclein (Figure 4.4D).
4.3.4 α-synuclein does not alter the characteristics of individual fusion pores
There are multiple mechanisms by which α-synuclein could alter the fusion pore to enhance the
efficiency of content release. It could provide energy for dilation increasing the speed of dilation for
the fusion pore. It could also passively stabilize the fusion pore in an enlarged state increasing the
amount of time content has to be ejected from the vesicle. Given our observation that α-synuclein
increases the total amount of time that docked vesicles spend with fusion pores open (Figure 4.4C),
passive pore stabilization seems most probable. To determine if α-synuclein was altering fusion
pores the duration of individual content releases, time to reach maximum dilation, and amount of
content releases was compared for SNAREs alone and in the added presence of α-synuclein.
When the duration of individual fusion pores was compared from SNAREs alone and with the
addition of α-synuclein there was no significant difference in their life-time. Fusion pores spent an
average of 1.1 ± 1.4 s open with SNAREs alone and 1.3 ± 1.4 s with α-synuclein (Figure 4.5A). The
time required for a content release event to reach its maximum fluorescence would correspond to
the time required for the fusion pore to reach maximum diameter. Fusion pore dilation facilitated












































































Figure 4.5: α-synuclein does not affect individual fusion pores. (A) The duration of individual
large fusion pores. This was measured as the time between the start of visible dye release to the end of
visible dye release. This was recorded for all large fusion pores, even when there were multiple releases per
vesicle. The duration of individual releases was unaltered by α-synuclein. It was 1.1 ± 0.5 s for SNAREs
alone and 1.2 ± 0.6 with the addition α-synuclein. (B) Amount of time required for large fusion pores to
reach maximum dilation. This was measured as the time from the start of dye visibly being released from
the first large fusion pore per vesicle to the maximum fluorescence for that event. The time required for
pore dilation was not changed by α-synuclein. It was 490 ± 190 ms with SNAREs alone and 480 ± 120 ms
with α-synuclein. (C) The relative amount of content release from the initial large fusion pore. This was
quantified the same way as in fig. 4D, but only for the first fusion pore. The relative amount of content
released from the first fusion pore was unaffected by α-synuclein. 61% ± 6% was released with SANREs
alone and 65% ± 5% in the presence of α-synuclein. A total of 725 individual events across 19 independent
recordings were analyzed for SNAREs alone and 681 events were analyzed across 33 independent recordings




























Figure 4.6: α-synuclein increase maximum fluorescent intensity of vesicles. (A) Drawing vesicles
closer to the bilayer would bring them further into the evanescent wave. (B) There is no correlation between
the maximum fluorescence for a vesicle and the number of content release events it has. (C) The cumulative
amount of time vesicles spent with large fusion pores open. This was quantified by summing the duration
of all large fusion pores per vesicles. α-synuclein increased the time from 410 ± 550 ms with SNAREs alone
to 1480 ± 710 ms with the addition of α-synuclein. (D) The relative amount of content released from
individual vesicles. This is calculated by subtracting the fluorescence at the end of the last content release
event from the maximum fluorescence and then dividing by the maximum. The maximum was defined as
the largest fluorescence during content release. The majority of vesicles with SNAREs alone did not release
any content (with an average of 25% release). α-synuclein shifted the vesicles to release much more of their
content (79%). A total of 725 individual events across 19 independent recordings were analyzed for SNAREs
alone and 681 events were analyzed across 33 independent recordings for the addition of α-synuclein.
α-synuclein could possibly increase the diameter of fusion pores and increase the amount of
content ejected for each release event. Of the docked vesicles that formed large fusion pores,
vesicles with SNAREs alone were capable of releasing on average 59 ± 24% of their (Figure 4.5C).
α-synuclein increased this to 62 ± 23%.
4.3.5 α-synuclein draws vesicles closer to the supported bilayer
We then investigate how α-synuclein increases the number of fusion pores that a vesicle forms.
One possibility is that α-synuclein could be drawing the vesicles closer to the bilayer and stabilizing
them there and thereby increasing the probability that a fusion pore would be able to dilate. TIRFM
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utilizes an evanescent wave to illuminate sample. This wave decreases exponentially, so drawing
fluorophores further into the wave even a small amount could greatly increase their fluorescence
(Figure 4.6A). If α-synuclein was drawing the vesicles closer to the bilayer, then vesicles in the
added presence of α-synuclein should have an greater average fluorescent intensity that those with
SNAREs alone. This is in fact the case (Figure 4.6B). Fluorescent intensities were compared relative
to vesicles that did not release content assuming that they did not cross the distance threshold to
form dilated fusion pores. Vesicles in the presence of αS had double the average relative max
intensity (1.2 for SNAREs alone; 2.5 with α-synuclein). 94% of the vesicles with α-synuclein had
intensities above vesicles that has no release. Only 52% of vesicles with SNAREs alone were able
to cross this threshold.
4.3.6 NMR reveals mechanism for molecular tethering
We then examined whether α-synuclein could bind to both the vesicle and supported bilayer
with greater effect than the SNARE complex. Hypothetically, α-synuclein could use both termini
to tether the opposing membranes together. The n-terminal could anchor α-synuclein to the plasma
membrane while the c-terminal binds to VAMP2 on the vesicle. This is the mechanism that we
sought to investigate through NMR.
To test this hypothesis and identify precisely the regions of α-synuclein involved in this process
we collected 1H-15N TROSY-HSQC spectra of 15N labeled α-synuclein mixed with phospholipid
bicelle, in the presence and absence of a soluble version of VAMP2 (VpS) (Figure 4.7A). VpS retains
the full N-terminus region of VAMP2 that is thought to interact with α-synuclein and its SNARE
motif (a.a 1-96). Only its transmembrane domain has been removed (a.a. 97-116). In the absence
of VpS, the recorded spectrum (Figure 4.7A and B) and calculated intensity profile (Figure 4.7C)
closely resemble the data reported by Bodner et al. (2009) demonstrating the binding of α-synuclein
to phospholipid membranes. We observed a strong attenuation of crosspeak intensity for residues
1-100, which confirmed that the N-terminal region of α-synuclein binds to our phospholipid bicelles.
Addition of unlabeled VpS resulted in a significant attenuation of the crosspeak intensity for residues
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15N α-synuclein + bicelles
15N α-synuclein + bicelles + VpS
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Figure 4.7: C-terminal residues 125 - 140 of α-synuclein interact with v-SNARE VAMP2.
(A) Overlay of 1H-15N TROSY HSQC spectra of uniformly 15N-labeled α-synuclein with bicelles, recorded
in the presence (red) and in the absence (blue) of 250 µM VpS. (B) Magnification of dense region of the
spectra showing the absence of significant chemical shift changes upon addition of VpS. (C) The intensity
of α-synuclein crosspeaks is plotted as function of residue number. A major decrease in peak intensity is
observed for residues 100-140 indicating this region of α-synuclein is interacting with VpS. (D) Relative
signal attenuation of α-synuclein crosspeaks is shown here as a function of residue number. The intensity
ratios were calculated for each crosspeak as the relative difference 1H-15N TROSY HSQC signals recorded
in the absence and in the presence of VpS.
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Figure 4.8: α-synuclein interacts with the linker region of v-SNARE VAMP2. (A) Overlay of
1H-15N TROSY HSQC spectra of uniformly 15N-labeled VpS with, recorded in the presence (red) and in
the absence (black) of 250 µM VpS. (B) Magnification of dense region of the spectra showing the absence
of significant chemical shift changes upon addition of α-synuclein. (C) Relative signal attenuation of α-
synuclein crosspeaks is shown here as a function of residue number. The intensity ratios were calculated for
each crosspeak as the relative difference 1H-15N TROSY HSQC signals recorded in the absence of and in the
presence of α-synuclein.
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123 - 140 of α-synuclein (Figure 4.7C and D) with no major chemical shift change (Figure 4.7B).
These results indicate that VpS binds to the C-terminal region of α-synuclein and that interaction
between the two proteins occurs on an intermediate exchange time scale (∼50-100 µs to 10 ms).
To identify the region of VpS that α-synuclein interacts with TROSY-HSQC spectra of 15N
labeled VpS with bicelles in the presence and absence of α-synuclein were collected. Similar to the
spectra collected with 15N labeled α-synuclein, the spectra of VpS did not display any chemical
shift perturbations (Figure 4.8A and B). Titration of α-synuclein caused attenuation of residues 82
- 94 of VpS demonstrating that α-synuclein specifically interacts with the linker region of VAMP2
between its SNARE motif and transmembrane domain (Figure 4.8C). The strongest attenuation
was focused on a trio of hydrophobic residues (Tyr 89, Trp 90, and Trp 91) suggesting that the
interaction is dependent on hydrophobic interaction.
4.3.7 C-terminal of α-synuclein is crucial for multiple content releases
Investigation with NMR revealed that a.a. 124-140 are responsible for interactions with the
SNARE complex. To evaluate the significance of this interaction we removed those residues (α-
synuclein ∆124). With the c-terminal removed, α-synuclein was still able to promote the majority
of vesicles to have content release (85%), but the number of vesicles that had multiple releases
drastically decreased from 55% with full length α-synuclein to 3% with α-synuclein ∆124 (Fig-
ure 4.9A). There was also an increase in the number of docked vesicles that did not release content.
Less than 1% of vesicles in with full length α-synuclein failed to have fusion pores dilate, while
15% of docked vesicles with α-synuclein ∆124 failed. The life time of content release events was
also significantly impacted by the truncation of the VAMP2 interaction region. The average life
time of content release events with full length α-synuclein was 2.3 s, but with the truncation this
decreased to 0.6 s (Figure 4.9B). The truncation was also detrimental to the amount of content
vesicles released returning it to SNARE alone levels. When only vesicles that had content release
were compared vesicles with SNAREs alone had an average release of 62% and α-synuclein ∆124


































































































Figure 4.9: Removal of the c-terminal of α-synuclein diminishes its ability to promote efficient
content ejection. (A) C-terminal of α-synuclein is responsible for α-synuclein promoting multiple releases
of content. α-synuclein promoted 99.6% of docked vesicles to form dilated fusion pores and 54.5% of docked
vesicles to have multiple releases of content. α-synuclein ∆124 still enables 85.1% of docked vesicles to release
content, but only 2.8% of vesicles have multiple releases. (B)Removal of the c-terminal of α-synuclein greatly
diminished the amount of time vesicles spent ejecting content. When only docked vesicles that had content
release were compared, the life time of content release events decreased from 2.3 s for α-synuclein to 0.6 s for
α-synuclein ∆124. (C) Again comparing only vesicles that released content, the truncation of the c-terminal
returned the amount of content vesicles released back to levels similar to SNAREs alone. α-synuclein ∆124
had an average release of 62% and SNAREs alone had an average of 63%. (D) Removal of the c-terminal of
αS increased the relative average maximum fluorescent intensity of docked vesicles. It was 1.2 for SNAREs
alone, 2.5 with α-synuclein-WT, and 3.0 with α-synuclein ∆124. A total of 725 individual events across 19
independent recordings were analyzed for SNAREs alone, 681 events were analyzed across 33 independent
recordings for the addition of α-synuclein, and 470 events were analyzed across 11 independent recordings
for α-synuclein ∆124.
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average maximum fluorescence intensity. It increased from 1.2 for SNAREs alone and 2.5 for full
length α-synuclein to 3.0 for α-synuclein ∆124 (Figure 4.9D).
4.4 Discussion
The aggregation of small neurological proteins has been of great interest in the field of neurology
for decades because of their putative role in dementia type diseases. The aggregates can interrupt
intercellular communication (11-13), alter the regulation of neurotransmitter release (Cabin et al.
(2002); Nemani et al. (2010); Larsen et al. (2006)), and can eventually lead to apoptosis (Zhou et al.
(2000); Lakso et al. (2003); Kirik et al. (2002)), but the investigation into the native and healthy
roles of the small proteins is relatively new. The aggregates of the Parkinson’s associated protein
α-synuclein halt neurotransmission (DeWitt and Rhoades (2013); Choi et al. (2013)), but there is
building evidence that its native role is to aid the SNARE complex: the machinery of membrane
fusion leading to a synapse (Burré et al. (2010); Lou et al. (2017); Hawk et al. (2019); Logan et al.
(2017); Burré et al. (2014)).
The addition of α-synuclein is able to overcome the SNARE complexes inefficiency at fusion
pore dilation. This should be distinguished from fusion pore generation. It has been demonstrated
that the SNARE complex is efficient at fusion pore generation, but unable to effectively drive fusion
pore dilation. The addition of α-synuclein increases the probability that a fusion pore will dilate
to from 37.8% with SNAREs alone to 99.6% and increased the average amount of content released
to increase from 23% to 74%.
This increase in efficiency of fusion pore dilation did not arise from α-synuclein directly altering
the individual content release events. The time required for the fusion pore to reach maximum
dilation is unaltered indicating that α-synuclein is not driving fusion pore dilation; the duration of
the release is not changed signifying that it does not stabilize the fusion pore halting its contraction;
the amount of content ejected by discrete releases was not affected demonstrating that the diameter
of the fusion pore was unchanged. α-synuclein must increase the dilation of SNARE dependent
fusion pores by some indirect means.
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Figure 4.10: Vesicle flattening during pore dilation. (A) Periphery SNARE complexes can utilize
their weak n-terminal interactions to stabilize the vesicle to the plasma membrane. The addition of α-
synuclein stabilizing the vesicle by burying its n-terminal in the plasma membrane and binding VAMP2
with its c-terminal promotes (B) the fluctuation of the fusion to larger diameters or (C) the formation of
multiple fusion pores per vesicle.
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Interaction between α-synuclein and the SNARE complex were observed to be crucial in this
process. NMR revealed that the end of α-synucleins c-terminal was used to interact with VAMP2:
specifically the last 20 amino acids. When they were removed from α-synuclein it could no longer
induce multiple content release events per vesicle or enhance the amount of content release as
efficiently. This demonstrates that the interaction between α-synuclein and VAMP2 on the v -
vesicle is vital for stabilizing the vesicle on the plasma membrane.
We can now expand our hypothesis that α-synuclein enhances SNARE activity to be significant
in all stages of the membrane fusion process. Even with SNAREs alone vesicles that generate large
fusion pores have a higher fluorescent intensity than those that do not. This suggests SNAREs
alone are capable of drawing vesicles toward the membrane, but are inefficient at this process. This
is most likely not dependent on the same set of SNAREs that generate the initial fusion pore, but on
peripheral SNARE complexes drawing down the edges of the vesicle ((Figure 4.10A)A). α-synuclein
could aid this process by providing additional tethers between the vesicle and plasma membrane.
Our observation could be explained by these additional tethers promoting fluctuation and dilation in
the fusion (Figure 4.10B), or by the generation of multiple fusion pores per vesicle (Figure 4.10C).
The first is probably the most physiologically relevant because in vivo neurotransmitter laden
vesicles are smaller than the vesicles used in our assay and, even with the addition force of α-
synuclein drawing toward the presynaptic membrane, they would not have sufficient surface area
for the generation of multiple fusion pores. So, increasing the probability of fusion pore dilation is
more significant than either the increased fluctuation of the fusion pore or formation of multiple
fusion pores.
In conjunction with the work of Logan et al. it has now been identified both in vivo and in
vitrothat α-synuclein increases the SNARE mediated release of content (Logan et al. (2017)). We
are also able to expand the molecular mechanism for how direct interaction between the v -SNARE
VAMP2 and α-synuclein facilitates this increase. Both the mechanism of this interaction and the
region of VAMP2 that α-synuclein binds to are yet unknown.
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4.5 Methods
4.5.1 Plasmid constructs for recombinant expression
DNA sequences encoding Rattus norvegicus VAMP2 (amino acids 1-116 with C103 replaced
by alanine), VpS (same sequence as VAMP2, but only a.a. 1-96), SNAP-25 (amino acids 1-206
with four native cysteines replaced by alanines), and encoding syntaxin-1A (amino acids 1-288 with
three native cysteines replaced by alanines) were inserted into a pGEX-KG vector as N-terminal
glutathione S-transferase (GST) fusion proteins. α-synuclein used in both the vesicle-to-bilayer
assay and NMR studies was encoded by the Homo sapiens SNCA gene. For the vesicle-to-bilayer
assay it was inserted into a pGEX-KG vector as a N-terminal glutathione S-transferase (GST)
fusion protein. The α-synuclein used for NMR spectra acquisition was inserted in a pET41a vector
and was untagged. Sequences for each construct were verified by the Iowa State DNA facility.
4.5.2 Recombinant protein expression and purification
4.5.2.1 SNARE Proteins
In brief, they were expressed in BL21 DE3 chemically competent E. coli, grown in LB (Luria-
Bertani) medium, and expression was induced with 300 µM IPTG (isopropyl β-d-thiogalacto-
pyranoside) once the optical density at 600 nm reached 0.6 - 0.8. Cells were isolated from solution
by centrifugation at 5,000 X g and lysed in high salt PBST (HSPBST) (497 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4, [4 g/L Triton-X 100 added for the membrane
proteins, VAMP2 and syntaxin-1A]) using homogenization. After centrifugation at 25,000 X g and
4 ◦C for 30 min., the lysate was incubated for 2 hours with 1 mL of glutathione-agarose beads
equilibrated in the same buffer used for lysis. The resin was then washed with 25 mL of lysis buffer
five times, and then equilibrated into HSPB-OG (exchanging 4 g/L Triton-X 100 for 0.8% octyl-
beta-glucoside[OG]) for the membrane proteins. Proteins were eluted from beads by cleavage with
30 U of thrombin at 4 ◦C for 16 hrs. Glycerol was added to the elutions for a final concentration of
15%, aliquoted, and stored at −80 ◦C.
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4.5.2.2 α-synuclein
Purification of α-synuclein for the vesicle-to-bilayer assay was purified in the same manner as
the SNARE proteins, but with an additional purification step. The elution was futher purified
using a custom poured size exclusion column packed with toyopearl HW-50F in a 2.5cm X 60cm
Chromaflex column. PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH
7.4) was used as the mobile phase. 5 mL fractions were collected and samples of each fraction were
run on a 15%-SDS-PAGE gel to identify fractions that lacked higher molecular weight species. Pure
fractions were combined and concentrated. After glycerol was add to a final concentration of 15%,
the proteins were stored at −80 ◦C.
Purification of the untagged α-synuclein for NMR spectra acquisition was grown in M9 minimal
media (6 g/L Na2HPO4 · 7 H2O, 3 g/L KH2PO4, 5 g/L NaCl, 1mM MgSO4, 100 µM CaCl2, 10.0
g/L perdeuterated D-glucose, and 5 g/L 15NH4Cl). BL21 DE3 E. Coli. were grown at 37
◦C until
an O.D measured at 600 nm of 1.2 was achieved. Expression of 15N labeled α-synuclein was induced
with 300 µM IPTG (isopropyl β-d-thiogalactopyranoside) and grown for an addition 6 hrs. Cells
were then harvested, resuspended in high salt PBS (497 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4
, 1.8 mM KH2PO4, pH 7.4), and lysed by homogenization. The cell lysis was then heated at 90
◦C
for 15 min. before centrifugation at 25,000 X g and 4 ◦C for 30 min. The supernatant was dialyzed
against 1 L off low salt PBS (buffer A) (6.4 mM Na2HPO4 , 3.6 mM KH2PO4, pH 6.5) at 4
◦C.
This was then loaded onto a Q-Sepharose column and washed with a 87% mix of buffer A and
13% of very high salt PBS (buffer B) (985.5 mM NaCl, 2.7 mM KCl, 6.4 mM Na2HPO4 , 3.6
mM KH2PO4, pH 6.5). Once the absorbance at 280 nm stabilized,
15N labeled α-synuclein was
eluted with a gradient of buffer A and B from 13% to 50% of buffer B over 80 mL. Fractions with
15N labeled α-synuclein were pooled and concentrated, buffer exchanged into diH2O with a size
exclusion column equilibrated with diH2O, and lyophilized. The protein was stored at −80 ◦C.
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4.5.3 Model membrane generation
4.5.3.1 Supported bilayer
The supported bilayer generated by drying of POPC (1-palmitoyl-2-dioleoyl-sn-glycero-3-
phosphatidylcholine), DOPS (1,2-dioleoyl-sn-glycero-3-phosphatidylserine), PIP2 (phosphatidyli-
nositol 4,5-bisphosphate), and PEG2000 (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000]) in a molar ratio of 78:15:2:5, drying under a stream of air, and
then stored under vacuum for 16 hours. This was resuspended in in HEPES (25 mM HEPES/KOH,
150 mM KCl, 1% β-OG, pH 7.4).
4.5.3.2 Unilaminar liposomes
Vesicles were made from a mixture of POPC, DOPS, and cholesterol at a molar ratio of 54:5:40.
This dried in the same manner as the supported bilayer. It was resuspended in HEPES and
30 µM Rhodamine B conjugated to 10 kDa dextran (RB-10K Dex). This was subjected to 10 flash
freeze/thaw cycles between liquid nitrogen and a 90 ◦C water bath and then extruded through 100
nm diameter polycarbonate filters to make unilaminar liposomes.
4.5.3.3 Bicelles for NMR
Bicelles were generated with a 0.35 ratio of long chain lipids to short chain lipids. A lipid film of
POPC and DOPS in a 1:1 molar ratio. This was dried in the same manner as with the supported
bilayer. It was then resuspended in DHPC (1,2-dihexanoyl-sn-glycero-3-phosphocholine) and stored
at 4 ◦C.
4.5.4 Membrane protein reconstitution into model membranes
4.5.4.1 t-SNARE supported bilayer
Syntaxin-1A and SNAP-25 were mixed in a 1:1.5 ratio maintaining the 0.8% OG concentration
by supplementing with 10% OG. This mixture was incubated at room temperature for 30 minutes to
form the t-SNARE complex. This was then added to the supported bilayer in a syntaxin-1A to lipid
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ratio of 1:2000. After incubating for 10 minutes, the mix was diluted to 3 times its original volume
with HEPES and then dialyzed overnight at 4 ◦C against HEPES with 2 g/L Bio-BeadsTMSM-2
Resin to remove all detergent.
4.5.4.2 v-SNARE vesicles
VAMP2 was mixed with the unilaminar liposomes at a 1:200 ratio maintaining a β-OG concen-
tration of 0.8% and 30 µM RB-10k Dex. This was then diluted to three times its original volume
by HEPES with 30 µM RB-10k Dex. This was dialyzed against the in the same conditions as the
t-SNARE supported bilayer.
4.5.5 Membrane protein reconstitution into model membranes
Hawk et al. (2019) previously detailed how the assay was conducted. In brief, the post-dialysis
t-SNARE supported bilayer was incubated in the flow cell, excess bilayer was washed out, and then
the post-dialysis content v -SNARE vesicle was flowed in at a rate of 50 µL/min. Flow was halted
upon observation of the first content release event and events were recorded for 60 seconds total
with a resolution of 20 ms per frame.
4.5.6 Analysis of recordings and pore dynamics
RB-10K dex fluorescence was measured to quantify content release events with a custom
MATLAB c© 2014(b) analysis software. Events were classified based on the number of content
releases by individual vesicles. All types had a rapid increase in fluorescence when the vesicle
docked to the supported bilayer. If content was released, then there was a rapid (within 2 sec.)
decrease in fluorescence. If not, then there was a slow decrease in fluorescence. Non-release events
had the initial spike in fluorescence, but did not decay indicating the lack of fusion pore formation.
The selected traces corresponding to content release events were background corrected. All the
traces for a recording were compared to find the minimum for each time point. A polynomial was
fitted to these minimums and then the polynomial was subtracted from each trace. The number of
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content release events were recorded during manual analysis. The cumulative amount of content
release for individual vesicles was quantified by dividing the difference in the maximum fluorescence
of a vesicle during content release (max) and the fluorescence at the end of the last release (min)
by the max. The amount of content release for the first release event was similarly calculated.
The max was defined as the maximum fluorescence during the first release and the min as the
fluorescence at the end of that release. The duration of release was quantified as the time from the
beginning of visible content release to the end of visible content release. The time of dilation was
calculated as the time from visible release initiation to maximum fluorescence.
4.5.7 NMR sample preparation and data acquisition
4.5.7.1 Samples
15N labeled α-synuclein was resuspended in 20 mM NaP pH 6.5 100 mM NaCl to a final
concentration of 150 µM of 15N labeled α-synuclein and 10 mM bicelles. 250 µM VpS was added
for their respective spectra. D2O was added to a final concentration of 10% for acquiring the lock
signal.
For the 15N labeled VpS reference spectra 15N labeled VpS was resuspended in 20 mM NaP
pH 6.5 100 mM NaCl to a final concentration of 200 µM. For the titration of α-synuclein spectra
15N labeled VpS was held constant at 150 µM while α-synuclein was added at 150 µM, 300 µM,or
600 µM for the respective 1x, 2x, and 4x α-synuclein titration spectra recordings. The same buffer
conditions were used as for the reference spectra. Amide assignments were derived for previously
published solution models Brewer et al. (2011).
4.5.7.2 Data acquisition
Spectra were collected at 298 K. 15N-TROSY-HSQC were collected on a Bruker Avance-AV





























































































































































Figure 4.11: Traces from vesicles with multiple content releases. Traces exemplifying the wide
range in the number of release events as well as the variable amount of time between releases. (A-B) Some
releases are very differentiated. (C-F) Others are more over lapped.
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and Wong, G. (2003). Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans
overexpressing human α-synuclein. J. Neurochem., 86(1):165–172.
Larsen, K. E., Schmitz, Y., Troyer, M. D., Mosharov, E., Dietrich, P., Quazi, A. Z., Savalle, M.,
Nemani, V., Chaudhry, F. A., Edwards, R. H., Stefanis, L., and Sulzer, D. (2006). α-Synuclein
overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a
late step in exocytosis. J. Neurosci., 26(46):11915–11922.
Lee, V. M. and Trojanowski, J. Q. (2006). Mechanisms of Parkinson’s Disease Linked to Patholog-
ical α-Synuclein: New Targets for Drug Discovery.
Logan, T., Bendor, J., Toupin, C., Thorn, K., and Edwards, R. H. (2017). α-Synuclein promotes
dilation of the exocytotic fusion pore. Nat. Commun., 20(5):681–689.
Lou, X. C., Kim, J., Hawk, B. J., and Shin, Y. K. (2017). Alpha-Synuclein may cross-bridge v-
SNARE and acidic phospholipids to facilitate SNARE-dependent vesicle docking. Biochem. J.,
474(12):2039–2049.
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll,
R. A., and Edwards, R. H. (2010). Increased Expression of α-Synuclein Reduces Neurotransmitter
Release by Inhibiting Synaptic Vesicle Reclustering after Endocytosis. Neuron, 65(1):66–79.
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). α-Synuclein
in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies.
Proc. Natl. Acad. Sci. USA, 95(11):6469–6473.
Zhou, W., Huribert, M. S., Schaack, J., Prasad, K. N., and Freed, C. R. (2000). Overexpression
of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized
mesencephalon-derived cells. Brain Res.
80
CHAPTER 5. FINAL DISCUSSION, CONCLUSION, AND THOUGHTS
FOR THE FUTURE
5.1 Thoughts
It was in the late 1990’s that α-synuclein was first linked to Parkinson’s disease and Lewy
body dementia (Spillantini et al. (1997)). Since then vast progress has been achieved. α-synuclein
is located in the presynaptic terminal (Maroteaux et al. (1988)) and it plays a role in stimulated
neurotransmitter release (Larsen et al. (2006)). Its lipid binding activity is important for its function
(Yavich et al. (2004)). α-synuclein’s can sense and form curvature in membranes enabling aggregates
to form pores in membranes (Varkey et al. (2010); Schmidt et al. (2012)). α-synuclein interacts
with the SNARE complex (Burré et al. (2010)) and its aggregates have been shown to inhibit
SNARE function (Choi et al. (2013)). More recently, Lou et al. determined that α-synuclein has a
concentration dependent effect on SNARE function (Lou et al. (2017)). It is becoming clear that one
of α-synuclein’s physiological functions involves participating or affecting the SNARE complexes’
function. The SNARE complex merges the membranes of neurotransmitter laden vesicles with
the neuronal presynaptic membrane. This releases the neurotransmitters into the synaptic cleft
generating a synapse. The SNARE complex generates energy for fusing the membranes not by
expending chemical energy, but through folding. The SNARE complex is made up of two halves:
one on the incoming vesicle (v -SNARE) composed of VAMP2 and another on the presynaptic
membrane (t-SNARE) comprised of syntaxin-1A and SNAP-25. VAMP2 and syntaxin-1A both
have a single SNARE motif and SNAP-25 has two. These motifs fold into a coiled-coil from their
membrane distal region toward their membrane proximal region. This zippering draws the opposing
membranes together until they eventual merge forming a fusion pore. Despite these advances it
was still unclear how α-synuclein was involved in this process: if it only affected a single step in
membrane fusion or impacted the whole process.
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In order to investigate the mechanism by which α-synuclein affects SNARE mediated membrane
fusion we developed a set of novel assays: one to measure and quantify membrane merger and the
other to observe and characterize fusion dilation and dynamics. The first relied on a fluorescent
lipid reporter. It allowed us to quantify the effect of α-synuclein on SNARE mediated vesicle
docking and merger. We found that α-synuclein greatly enhanced the amount of merger activity.
After analysis we were able to differentiate between when a vesicle docked and when it progressed to
merging with the plasma membrane. The increase in activity that we initially observed was entirely
dependent on α-synuclein increasing the amount of vesicles that docked to the membrane. It did
not affect the merger process after docking leaving the probability and speed of merger unchanged.
Encapsulating a soluble reporter into vesicles then allowed us to monitor the subsequent forma-
tion and dilation of the fusion pore. Interestingly, the SNARE complex was not able to promote
the continued dilation of the fusion pore. Most of the vesicles that docked did not form a dilated
fusion pore. α-synuclein was able to augment the SNARE complex and promoted >99% of the
vesicles that docked to form dilated pores. Characterization of discrete vesicle events allowed us to
determine that α-synuclein was affecting the number of fusion pores formed per vesicle while not
altering the qualities of individual fusion pores. This leads to an increased amount of fluorophore
that was released without increasing the efficiency of individual fusion pores.
It has previously been hypothesized that α-synuclein would be able to function as linker between
the vesicle and the plasma membrane (Lou et al. (2017)). Our work with studying lipid merger
also confirmed earlier findings that α-synuclein did not affect membrane merger beyond enhancing
vesicles docking to the surface (Lou et al. (2017)). With our content release assay we were able to
expand this hypothesis to incorporate the concept that α-synuclein stabilizes the vesicles on the
plasma membrane. There is significant evidence that α-synuclein can regulate the pool of vesicles
ready for use in neurotransmission and that removal of α-synuclein hinders prolonged stimulated
release (Murphy et al. (2000); Cabin et al. (2002); Nemani et al. (2010); Scott and Roy (2012)).
The hypotheses that α-synuclein regulates the vesicle pool are based on the observation that in the
presence of α-synuclein there is an increased number of vesicles near the presynaptic membrane.
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This could also be explained by our observation that α-synuclein increased the number of vesicles
that dock to the plasma membrane. Furthermore, this could also explain the more rapid depletion
of vesicle primed for prolonged stimulation. Without the increased number of vesicles bound to
the plasma membrane, the time required for vesicles to diffuse to the presynaptic would hinder the
speed of regeneration of primed vesicles.
The other significant finding from our work is that SNAREs and other auxiliary factors may
flatten the vesicle into a discus shape. The Ca2+ sensor that enables synchronous fusion,
synaptotagmin-1, seems to enhance content ejection from vesicles by stabilizing the curvature of
the fusion pore. This direct stabilization of the fusion pore increases both the speed and efficiency
of evacuation. It is definitely a fusion pore dilator in the classical sense that its direct interaction
with fusion pore enhances fusion. This is not the case for α-synuclein. It has been observed that
α-synuclein can increase the amount of content released for stimulated exocytosis (Logan et al.
(2017)). Our observations agree with this, but not because α-synuclein is directly affecting the
fusion pore. It more indirectly increases content release by promoting the formation of multiple
fusion pores per vesicle. To my knowledge it has not been proposed that more than a single
fusion pore could form per vesicle, but it does unify the observations that α-synuclein has no affect
the speed of the content release or the membrane merger process, while increasing the amount of
content released from a cellular system (Lou et al. (2017); Lou et al. (2017); Hawk et al. (2019)).
Since α-synuclein was found to be the major component of Lewy bodies, the focus has been how it
causes Parkinson’s. We have been able to answer how α-synuclein aggregates are toxic, how they
kill cells, and have been able to with reasonable certainty conclude that α-synuclein assists the
SNARE complex by stabilizing vesicles on the presynaptic membrane.
I believe that it is now time to shift the focus away from α-synuclein. In physiological conditions
it is very slow to aggregate, and if aggregation was solely responsible for the onset of Parkinson’s,
it would be much more prevalent. Instead I propose that there is another mechanism at work that
under normal physiological conditions keeps α-synuclein from aggregating, breaks them back into
monomers, or degrades the aggregates. This should be the next target of study. What is this
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system and how is it overwhelmed? Keeping this system functioning would prevent Parkinson’s
disease or restoring its function may even be able to halt the progression of dementia.
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A.1 Abstract
SNARE complex formation, which is believed to drive intracellular membrane fusion, transits
through multiple conformational states along the membrane fusion pathway. The SNARE interme-
diates are biologically important because they serve as targets for fusion regulators and clostridial
neurotoxins. Spin labeling EPR has contributed significantly to the understanding of the struc-
tures and the dynamics of SNARE intermediates. In particular, the EPR lineshape analysis, which
is highly sensitive to protein conformational changes such as the local coil-to-helix transition, has
revealed the sequential compacting steps leading to formation of the highly stable four helix bundle.
A.2 Introduction
A.2.1 Layered complexity of SNARE complex formation
It is now widely believed that SNARE proteins, which are highly conserved from yeast to
human, drives intracellular membrane fusion Söllner et al. (1993); Weber et al. (1998). The vesicle
(v -)SNARE protein associates with the target membrane (t-)SNARE proteins to form a complex
that brings about apposition and subsequently, fusion of two membranes. The SNARE complex
86
is the fusion machine that provides the necessary free energy to overcome the energy barrier for
fusion of two separate membranes that are otherwise individually highly stable when undisturbed.
The most critical piece of information to understand the mechanism of SNARE-dependent
membrane fusion may be the three dimensional structure of the SNARE complex. The SNARE
core complex is a highly stable, all parallel four-stranded coiled coil Poirier et al. (1998); Stein et al.
(2009); Sutton et al. (1998) that forms its parallel structure when it brings two membranes into
close proximity. The high stability of the structure ensures the merge of two membranes. This
stable formation justifies its structural and energetic role as the core fusion machine.
Equally important is the pathway through which the SNARE complex is assembled. Some
SNARE-dependent membrane fusion (for example, synaptic vesicle fusion) is tightly regulated by
auxiliary proteins including Ca2+-sensor synaptotagmin 1 and sec1/munc (SM) family proteins
Südhof and Rothman (2009). It is believed that auxiliary proteins target the SNARE folding inter-
mediates Lou and Shin (2016). Thus, the structural investigations of SNARE folding intermediates
appear to be essential towards the understanding of the mechanisms whereby the auxiliary proteins
regulate membrane fusion.
At early stages, two t-SNARE proteins, one in the syntaxin family and the other in the SNAP-
25 family, assemble into a 1:1 t-SNARE complex, which will serve as the receptor for v-SNARE. In
the t-SNARE complex, one SNARE motif (∼70 residue-long heptad repeat) from the syntaxin-1A
and two N- and C-terminal SNARE motifs from SNAP-25 form a highly dynamic, three-stranded
coiled coil, where the C-terminal SNARE motif of SNAP-25 has tendency to uncoil to a great extent
An and Almers (2004); Khounlo et al. (2017); Khounlo et al. (2017). Adding to the complexity,
there is evidence that association of v-SNARE with the t-SNARE complex occurs in multiple (at
least two) sequential steps: The assembly starts from the membrane-distal N-terminal region and
proceeds towards the membrane-proximal C-terminal domain Sørensen et al. (2006), thereby driving
a gradual apposition of two membranes. The folding intermediates are likely to be transient and
meta-stable and thus, offer formidable challenges for structural investigations Gao et al. (2012);
Min et al. (2013); Shin et al. (2014).
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A.2.2 Spin labeling EPR on SNARE complex formation
Over the years, spin labeling EPR has contributed significantly to the understanding of the
structure and dynamics of the SNARE core complex and its folding intermediates. In site-directed
spin labeling EPR Hubbell et al. (1998), a specific, selective residue is replaced with a unique
cysteine and the cysteine is labeled with an EPR-active nitroxide. EPR of spin labeled mutants
offers three powerful experimental avenues to explore the structure and the function of SNARE
complexes McHaourab et al. (2011). The first is the distance measurement between two site-
specifically attached nitroxides within the complex Rabenstein and Shin (1995). The distance
measurement method has been used to determine the first four-helix bundle structure of the SNARE
core complex Poirier et al. (1998), the structure of the t-SNARE complex that is consist of syntaxin
and SNAP-25 in the 2:1 stoichiometry Xiao et al. (2001); Zhang et al. (2002), and the conformational
change of the transmembrane domain (TMD) of v -SNARE caused by cholesterol Tong et al. (2009).
The detailed methods and the experimental protocols are extensively described in the Method in
Molecular Biology article by Mandal et al. (2019).
The second is the measurements of accessibilities to non-polar O2 and polar, soluble param-
agnetic NiEDDA, the ratio of which is used to measure the membrane immersion depth of the
nitroxide attached to the membrane-embedded polypeptide Altenbach et al. (1994). The method is
grossly empirical. Nevertheless, it has proven to yield fairly accurate estimation of the membrane
immersion depth. To be an effective fusion machine, the SNARE complex must be able to transfer
the force generated by the core region to the transmembrane domains. We believe that the linker
region acts as the force transducer. The EPR accessibility measurements reveal that despite highly
basic nature of the both v - and t-SNARE linker regions, they are immersed into the membrane
with some secondary structures Chen et al. (2004); Kim and Shin (2017); Kweon et al. (2002, 2003).
Thus, they help make a tight connection between the SNARE core and the transmembrane domain
and may structurally qualify as the effective force transducer. Furthermore, the determination of
the structure of the v-SNARE TMD laid the groundwork for designing the mutant that traps the
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hemifusion intermediate, leading to the first time discovery of hemifusion in SNARE-dependent
membrane fusion (Xu et al. (2005)).
A.2.3 EPR lineshape analysis to peel off layers of SNARE complex formation
The third avenue, which is the main focus of this chapter, is the EPR lineshape analysis, taking
advantage of the EPRs superb sensitivity to the motional rate of the nitroxide (Columbus and
Hubbell (2002)). For example, the folding of a polypeptide from a random coil to an α-helix or
the binding of the unstructured polypeptide to the membrane gives rise to a dramatic lineshape
change from a narrow, fast motional spectrum to a fairly broad, intermediate motional spectrum,
which are visually distinguishable from each other. If the nitroxide makes an additional tertiary
or steric contact, the lineshape change is even more profound to become very broad which reflects
very severely restricted motion. SNARE complex formation involves these types of conformational
changes which are accompanied by dramatic EPR lineshape changes for the nitroxide attached to
SNARE motifs.
SNARE motifs, when not in the complex, are mostly unstructured and freely moving in solution,
resulting in sharp, fast motional EPR spectra for the nitroxides. However, when complexed with
other SNARE partners, the motional rate of the nitroxide slows down significantly and the EPR
lineshape becomes broad (Chen et al. (2004); Kweon et al. (2003)). Very interestingly, however for
long SNARE complexes in particular, a conformational change could be localized specifically to a
certain part of the protein. For example, SNARE zippering is expected to transition through a par-
tially folded conformation in which the N-terminal coiled coil is intact while the C-terminal region
is frayed. The EPR lineshape analysis is uniquely suited to investigate such local conformational
changes and has proven powerful in characterizing the structures of SNARE folding intermediates
(Khounlo et al. (2017); Zhang et al. (2005)).
For the SNARE complex, its working environment is the narrow gap between two closely ap-
posed membranes. However, most structural studies have been carried out by employing isolated
proteins, away from such a special situation. Thus, more often than not, the interpretation of the
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structural outcomes is often ambiguous. Alternatively, the recently advanced nanodisc technology
makes it possible to create the membrane platform that mimics the native-like environment for
SNARE complexes. One could place a single SNARE complex within a two nanodisc sandwich by
reconstituting v - and t-SNAREs to separate nanodiscs and allowing them to form the trans com-
plex between the two nanodiscs. Such an experimental platform has been successfully constructed
and the structure of the SNARE complex has been examined using the EPR lineshape analysis
(Shin et al. (2014)). The results are exciting and reveal that a half zippered SNARE complex in
which the C-terminal half of v -SNARE, which is the downstream of conserved middle 1R3Q layer,
is free while the N-terminal half of the SNARE complex is an intact coiled coil has been identified
as a likely metastable fusion intermediate.
Although the lineshape analysis is the least explored avenue of spin labeling EPR in structural
biology, it has been instrumental in characterizing the structure and the dynamics of SNARE
folding intermediates in the native-like environment. Additional contribution with this approach
include, but not limited to, the characterization of partially folded t-SNARE core (Khounlo et al.
(2017)) and structural disruption of the C-terminal region of the SNARE complex by the membrane
(Zhang et al. (2005)). Overall, EPR has shown to be a powerful technique in observing the structural
transitions in SNARE complex formation (Figure A.1). In this chapter, we will review the protocols
of the sample preparations, EPR experiments, and data analysis for the EPR lineshape analysis on
SNARE proteins.
A.3 Materials
1. Primers: Synthesized by the Iowa State DNA facility.
2. QuikChange Kit: Agilent Technologies QuikChange Site-Directed Mutagenesis Kit.
3. Thermocycler: MJ Mini Thermal Cycler.
4. Restriction enzyme Dpn1: FastDigest DpnI.
5. PCR cleanup kit: QIAquick PCR Purification Kit.
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Nitroxide Side ChainA




Figure A.1: Exploring the pathway of SNARE complex formation with SDSL EPR. (A) Diagram
of a disulfide-linked nitroxide side chain (MTSSL). (B) The t-SNARE is in a state where the C-helix (SC)
of SNAP-25 is unstructured and highly dynamic. The dynamic structure of the SC domain was investigated
by attaching a nitroxide spin label to a site-specific cysteine. (C) The t-SNARE is in a state where the
SC is in a structured -helix. The nitroxide spin label is sensitive to the local environment and produces a
broader EPR lineshape than the dynamic SC does. The EPR lineshape analysis revealed that the SC is in
a dynamic equilibrium, alternating between a bound and an unbound state. (D) Dynamic trans-SNARE
complex in which the N-terminal of VAMP2 is locally structured, but the C-terminus is locally dynamic.
The structured t-SNARE complex is the precursor for VAMP2 binding and SNARE complex formation.
When VAMP2 binds, SNARE zippering occurs from the N- to C-terminus. This pre-fusion state of the
SNARE complex was studied using a SNAREpin formed in the chasm of two nanodiscs. (E) Structured
trans-SNARE complex. The nanodiscs allow the SNARE proteins to form the stable four helix bundle, but
stop the full progression by arresting it at a half-zippered state. (F) Cis-SNARE complex. A stable four
helix bundle as a post-fusion complex. The post-fusion state of the SNARE complex was studied within a
single nanodisc.
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7. 10 mg/mL tetracycline: 100 mg of tetracycline is added to a final volume of 10 mL of double-
deionized water (ddH2O). Store at −2 ◦C.
8. E.coli XL1 Blue and BL21 DE3 competent cells.
9. Luria broth (LB): 25 g/L of premixed 10 g/L casein digest peptone, 10 g/L sodium chloride,
and 5 g/L yeast extract are dissolved in ddH2O and autoclaved.
10. 100 mg/mL ampicillin: 1 g of ampicillin is dissolved into a final volume of 10 mL ddH2O.
Store at −20 ◦C.
11. 50 mg/mL kanamycin: 0.5 g of kanamycin is dissolved into a final volume of 10 mL ddH2O.
Store at −20 ◦C.
12. QIAprep Spin Miniprep Kit.
13. 1 M isopropyl-β-D-thiogalactopyranoside (IPTG): 2.38 g of IPTG is dissolved in a final volume
of 10 mL ddH2O. Store at −2 ◦C.
14. Centrifuge and rotors: A Beckman Coulter Avanti J-25 centrifuge is used in conjunction with
a JA-14 rotor for cell pelleting and a JA-25.5 rotor for spinning down cell lysate.
15. 10X Phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, and 1.8
mM KH2PO4 with a pH of 7.4. The pH is not adjusted. Store at 4
◦C.
16. Phosphate-buffered saline with triton (PBST): Generated from 10X PBS. Final concentration
of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4 and 0.4% Triton X-100
with a pH of 7.4. Store at 4◦C.
17. 1 M DL-dithiothreitol (DTT): 1.54 g of DTT is dissolved in a final volume of 10 mL ddH2O.
Store at 20◦C.
18. AEBSF: 0.25 g of AEBSF is dissolved in a final volume of 5 mL ddH2O. Store at 20
◦C.
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19. 20% N-lauroylsarcosine: 2 g of N-lauroylsarcosine is dissolved in a final volume of 10 mL
ddH2O. Store at 4
◦C.
20. GSH beads: Glutathione Agarose Beads.
21. Phosphate-buffered saline with N-ocytl-B-D-glucopyranoside (PBS-OG): Generated from 10X
PBS. Final concentration of 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4
and 0.8% OG with a pH of 7.4. Store at 4◦C.
22. Thrombin.
23. Glycerol.
24. Bio-rad RC DC Protein Assay Kit II.
25. Spin concentrators: Amicon c© Ultra - 0.5mL Centrifugal Filters Ultracel c© - 3K.
26. Desalting column: PD MiniTrapTM G-25 (GE Healthcare).
27. 100 mM MTSSL: 50 mg methanethiosulfonate (MTSSL) (Fisher Scientific) is added to 1.89
mL of acetonitrile. Store at 20◦C wrapped in aluminum foil.
28. 100 mM TEMPOL: Add 172 mg of 4-Hydroxy-TEMPO (Sigma Aldrich) to a final volume of
100 mL ddH2O. Store at 4
◦C.
29. Bruker Elexsys E500 X-band EPR spectrometer equipped with the loop-gap resonator (Med-
ical Advances) and a low-noise microwave amplifier (Militech).
30. XEPR: Bruker Xepr software suite version 2.6b.54 is used in Linux (OpenSuse 11.3).
31. Lipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-dioleoyl-sn-glycero-
3-phospho-L-serine (DOPS) are removed from their vials and transferred to amber, glass bot-
tles. All bottles are capped, sealed with parafilm, and vacuum sealed for storage. Store at
20◦C in the dark.
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32. 100 mg/mL cholesterol: 100 mg of cholesterol powder is dissolved to a final volume of 1 mL
using chloroform in an amber, glass bottle. All bottles are capped, sealed with parafilm, and
vacuum sealed for storage. Store at 20◦C in the dark.
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35. Phosphate-buffered saline (10% OG): 100 mg of OG is added to 100 µL of 10X PBS. The final
volume is adjusted to 1 ml with ddH2O. Store at room temperature.
36. 500 µM sodium cholate: 3α,7α,12α-Trihydroxy-5β-Cholan-24-Oic Acid (Anatrace). 215 mg
of sodium cholate is dissolved in a final volume of 1 mL using T150. It is very important
that this comes from a company that synthesizes it, not one that purifies it from a biological
source. The enzyme contaminants in the biologically purified sodium cholate will degrade
lipids and membrane proteins.
37. Apo-A1 is recombinantly expressed and purified (see Note 10).
38. T150 buffer: 10 mM tris base and 150 mM sodium chloride. This pH is adjusted to 7.4. Store
at 4◦C.
39. Bio-Beads: Bio-Beads SM-2 Resin (Bio-Rad). A 1:1 solution of bio-beads in T150 is made by
treating the bio-beads with methanol to remove air and equilibrating to desired buffer. Add
10 mL of bio-beads to a 25 mL batch column. The bio-beads are washed with 10 column
volumes (CV) of methanol, ensuring that the bio-beads are constantly submerged. At the
end of the last wash, immediately wash with another 10 CV of T150 (or buffer of choice).
Near the end of the last wash, cap the tip of the column, fill the column 20 mL with T150
(or buffer of choice), and transfer the bio-beads to a 50 mL tube for storage at 4◦C.
40. FPLC: BioLogic DuoFlow 10 System Fraction collector (Bio-Rad).
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41. Size exclusion column (SEC): GE Healthcare Life Science Superdex 200 10/300 GL.
42. Ni-NTA Agarose Resin: Thermo Scientific HisPur Ni-NTA Resin.
43. 5 M imidazole: 17.02 g of imidazole is dissolved in a final volume of to 50 mL ddH2O. The
pH is corrected to 7.4. Store at 4◦C wrapped in aluminum foil.
44. EPR sample loading tips: Fisherbrand Gel-Loading Tips, 0.5-10 µL.
45. Capillary tubes: Borosilicate capillary tubes with an internal diameter (i.d.) of 0.6 mm and
an outer diameter (o.d.) of 0.84 mm (VitroCom) are sealed at one end with a Bunsen burner.
46. Ethanol.
A.4 Methods
A.4.1 Generation of cysteine mutant plasmid
1. Design primers (see Note 1).
2. Site-directed mutagenesis. The thermocycler is set at following protocol: Heat lid to 105◦C,
98◦C for 2 minutes, 98◦C for 15 seconds, 55◦C for 1 minutes, 68◦C for 5.5 minutes, repeat
steps 2-4 for 16 cycles (17 cycles in total), 68◦C for 11 minutes, 4◦C until stopped.
3. Transformation into E. coli XL1 Blue competent cells (see Note 2). 100 ng of purified mu-
tant plasmid is transformed into ∼50 µL XL1 Blue competent cells. Transformed cells are
incubated with 1 ml Luria Broth (LB) at 37 ◦C for 1-2 hrs. shaking at 200 rotations per
minute (rpm). After incubation, the cells are plated onto ampicillin plates and incubated
upside down at 37 ◦C for 16-18 hrs.
4. Screen for the desired mutation. Pick off 3-5 isolated colonies with different sterile pipette
tips and add each colony to separate 50 mL sterile tubes containing 10 ml LB-amplicllin
(100 µg/mL). Cap the tubes, but do not screw on the cap tightly. If necessary, tape the cap
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on to prevent it from falling off. Incubate the colonies for 16-18 hrs. at 37 ◦C while shaking
at 200 rpm.
5. Purifying amplified plasmids. The QIAprep Spin Miniprep Kit and protocol are used
(QIAprep
TM
Miniprep Handbook). The DNA concentration is measured using a Nanodrop
in the dsDNA nucleic acid mode.
6. Plasmids are sequenced by the Iowa State University DNA facility using Sanger Sequencing
and sequences are aligned with the wild-type sequence to verify that only the desired mutation
is made.
A.4.2 Purification of recombinant proteins
1. Transform verified cysteine mutant plasmid into E. coli BL21 (DE3) competent cells.
2. Grow the starter culture. Follow the same protocol as 3.1 step 4.
3. Grow a large culture. Inoculate 500 mL of LB-amp with 5 mL of the starter culture and
incubate at 37 ◦C while shaking at 200 rpm until the optical density at 600 nm (OD600)
reaches 0.6-0.8. Chill for at least 30 minutes at 4 ◦C, induce with 150 µL of IPTG (1 M), and
incubate at 16 ◦C and 200 rpm for 16-18 hrs..
4. Lyse the cells. After induction, pour out the large culture into 250 mL centrifuge tubes.
Pellet the cells by centrifuging at 4◦C for 10 minutes at 3,800 x g in a JA-14 rotor. Once cells
are pelleted, pour out the supernatant and resuspend the cells in 20 mL of lysis buffer (see
Note 3). Add 75 µL DTT (1 M), 30 µL AEBSF (50 mg/ml), and 150 µL N-lauroylsarcosine
(20% w/v) to the resuspended cells. Lyse cells using a homogenizer. Lysate should change
from a viscous opaque color to a fluid clear color indicating successful lysis.
5. Bind protein to affinity beads. Add the lysate to 50 mL centrifuge tubes and centrifuge with
at 4 ◦C for 30 minutes at 27,200 x g in a JA-25.5 rotor. While the lysate is centrifuging,
add ∼1 mL of GSH beads to a 25 mL batch column and wash with 3 column volumes
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(CV) of ddH2O, then 1 CV of lysis buffer to equilibrate the column ensuring the beads
stay continuously hydrated. Cap the tip of the column and add the supernatant from the
centrifuged lysate to equilibrated beads. Cap the top of the column and nutate the mixture
at 4 ◦C for ∼2 hrs.
6. Purify the protein of interest. After ∼2 hrs., drain the supernatant from the column by first
removing the cap from the top of the column and then the cap from the tip of the column.
Wash the beads with 5 CV of lysis buffer. After washing, the beads are buffer-exchanged
into their elution buffers (see Note 3). Buffer exchange by adding three 1 mL aliquots to the
washed beads. Let each aliquot fully flow through before adding the next. Cap the tip of
the column and add 1 mL of elution buffer and 30 µL of thrombin (1U/µL) to the buffer-
exchanged beads. Cap the top once all the contents are added. Cleave off the purified protein
by either incubating the column at room temperature for 1.5 hrs. or 4 ◦C for 16 hrs. Ensure
homogenous distribution of the thrombin by cleaving on a nutator.
7. Elute purified protein. Remove the cap off the top of the column first and then remove the cap
off tip of the column over an Eppendorf tube to collect the first fraction. Elute the remaining
protein by adding 1 mL aliquots of the elution buffer to the beads and collecting. Significant
amounts of protein should appear in the first three fractions. Add 177 µL of glycerol to each 1
mL fraction making the final solution 15% glycerol (v/v). Glycerol serves as a cryo-protectant
for storage at −80 ◦C.
8. Check the protein purity. Hand cast 12% SDS-PAGE gels according to the Bio-Rad protocol
(Bio-Rad: Handcasting Polyacrylamide Gels). Aliquot out 10 µL of the eluted protein (see
Note 4). Add 5X SDS-PAGE loading dye to purified protein so that volume ratio of dye to
protein is 1:4. Load the gel into the electrophoresis system and load the entire protein-dye
sample along with a protein ladder into the wells. Run at 40 mA for 35 min. for a single gel
or 60 min. for two.
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9. Estimate the protein concentration. Use the Bio-Rad RC DC kit (Bio-Rad: RC DC Protein
Assay) and protocol to estimate the protein concentration. Concentrate and store at −80 ◦C
(see Note 5).
A.4.3 Spin labeling recombinant proteins
1. Reduce protein for efficient spin labeling. An aliquot of purified protein is thawed on ice. The
protein is then diluted to a final volume of 500 µL in a solution of PBS + DTT (5 mM). This
mixture simultaneously reduces the cysteines and prepares the protein for the PD-10 desalting
column. The mixture is incubated for 30 minutes at 4 ◦C. While the protein is being reduced,
the desalting columns are prepared by pouring off the storage buffer and equilibrating with
3 CV of elution buffer. Calculate the volume of MTSSL in order to have the spin label :
protein ratio at 10 : 1 (see Note 6). After incubation, the mix is added to the equilibrated
desalting column. Once the mixture has fully loaded into the column, 1 mL of elution buffer
is used to elute the reduced protein off the column. The flow through from this step contains
the reduced protein and should be collected.
2. Spin label reduced protein. Add the calculated volume of MTSSL as soon as reduced protein
elutes from the desalting column. The protein is spin labeled overnight by nutating for 16-18
hrs. at 4 ◦C.
3. Remove excess spin label. Concentrate the labeled protein to 500 µL using a 3K spin con-
centrator. During the centrifugation, prepare another desalting column as in 3.3 step 1. A
concentration cycle should be about 14,000 x g at 4 ◦C for 8 min. with resuspension between
cycles to prevent aggregation. Load the concentrated spin labeled protein onto the equi-
librated PD-10 desalting column. This desalting column removes a majority of the excess
MTSSL from the labeled protein. Elute the spin labeled protein and collect.
4. Remove residual excess spin label. Spin wash the eluted labeled protein by concentrating it
to ∼250 µL in a new 3K spin concentrator and then filling the remaining portion of the spin
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concentrator full of elution buffer. Use the same concentration cycle procedure as in 3.3 step
3. Three spin wash cycles should remove the remaining of excess MTSSL. Re-estimate the
protein concentration using the Bio-Rad RCDC kit (Bio-Rad: RC DC Protein Assay).
5. Measuring labeling efficiency (see Note 7). EPR spectra of TEMPOL standard solutions of
known concentrations are collected. The EPR spectra are processed by correcting for the
baseline and double integrating. These double integration values are plotted against the spin
concentrations to generate a standard curve. The EPR spectrum of the spin labeled protein
of a known protein concentration is measured and processed under the same conditions as
the TEMPOL standards. The spin label concentration of the protein sample is determined
by comparing its double-integration value with the TEMPOL standard curve. The spin label
concentration of the protein sample is then divided by the protein concentration determined
by the Bio-Rad RCDC kit (Bio-Rad: RC DC Protein Assay) to obtain the spin-labeling
efficiency. Spin labeling efficiencies using our method are usually over 90%.
A.4.4 Reconstitution of spin labeled protein into nanodiscs
1. Prepare the stock lipid mixture. Lipids are carefully mixed in a glass tube so that when
resuspended in 100 µL of T150 buffer, the total lipid concentration is 50 mM. The final lipid
mixture of PC : PS : cholesterol is at a molar ratio of 65 : 15 : 20. The chloroform in the
mixture is evaporated under an air stream to dry the lipids. The dried lipid film is placed
in a vacuum desiccator at room temperature overnight (16-18 hrs.) (see Note 8). Resuspend
with 100 µL of T150 buffer by incubating in a 42 ◦C water bath for 1 minute and vortexing
for 1 min. Repeat until the lipid film has been resuspended. The lipid stock can be stored at
−80 ◦C for ∼2 weeks.
2. Preparing nanodisc mixture. Section 3.4 steps 2-3 are summarized in Figure A.2. The goal
is for the end product of lipids : labeled protein : Apo-A1 to be at a molar ratio of 400 : 1 :




































Figure A.2: Reconstitution of SNARE proteins into a lipid nanodisc. A step by step flow chart for
the reconstitution of full-length SNAREs into lipid nanodiscs.
to sodium cholate so that the final concentration of sodium cholate in the nanodisc mixture
is 50 mM. This mixture is incubated on ice for 5 min.
3. Adding SNAREs to the nanodisc mixture (see Note 9). The v- and t-SNARE proteins are
added to the separate sodium cholate lipid mixtures. The proteins are added in a lipid :
protein ratio of 400 : 1. When incorporating the t-SNARE proteins, Stx is used to determine
the 400 : 1 ratio. This mixture is incubated on ice for 5 minutes. Apo-A1 (see Note 10) is
added to the mixture in a lipid : Apo-A1 ratio of 100 : 1 and it is incubated on ice for 5
minutes. His-tagged Apo-A1 is used when incorporating t-SNAREs and untagged Apo-A1 is
used for v-SNARE when forming the trans-SNARE complex between two nanodiscs with the
intention to purify the complex with the Ni-NTA column.
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4. Reconstitution of labeled SNAREs into nanodiscs. Bio-beads are added to the mixture at
a 1 : 2 volume ratio. This is incubated on ice for 5 minutes and shortly spun to pellet the
bio-beads. Repeat the same process on the supernatant using the same amount of fresh bio-
beads. It is easier to collect the supernatant from the bio-beads if a small cavity is made in
the pelleted bio-beads (see Note 11). The supernatant volume is either concentrated to 120
µL using a spin concentrator or diluted to 120 µL with T150 buffer. Filter supernatant with
a Spin-X centrifuge filter and store on ice.
5. Purification of SNARE-reconstituted nanodiscs using size exclusion chromatography. All
samples used on the size exclusion column (SEC) must be filtered and buffers must be both
filtered and degassed. Filter and degas 500 mL of T150. Wash SEC with 2 CV of filtered and
degassed T150 at 0.5 mL / minute. Inject the sample into the sample loop and load with 2
mL of T150 at the 0.5 mL / minute flow rate. Elute with 1.5 CV of T150 at the flow rate of
0.5 mL / minute. Nanodiscs usually elute between the 12-14 mL fractions.
6. Form trans-SNARE complex within two nanodiscs. This step can be skipped if only
a single species of the nanodisc is desired. ∼1 mL of Ni-NTA beads is added to a
25 mL batch column, washed with 2 CV of ddH2O, and equilibrated with 1 CV of T150.
The tip of the column is then capped. Both v-SNARE nanodiscs and t-SNARE nanodiscs
purified from FPLC are added to the Ni-NTA beads, the top of the column capped, and the
mixture is nutated overnight at 4 ◦C. The top of the column is first opened and then the tip
removed from the bottom allowing unbound nanodiscs to run off the column. The remainder
of unbound nanodiscs are washed off with 2 CV of T150 buffer. The nanodiscs that have
formed the trans-SNARE complex are eluted with 300 mM imidazole in T150 buffer.
A.4.5 Electron paramagnetic resonance (EPR)
1. Prepare samples for EPR. This process is summarized in Figure A.3. Pipette up 10 µL of
sample into EPR tube loading tips. Take the loaded EPR loading tip and put it in the open





loading tip with sample
Figure A.3: Preparation of the sample tube for EPR. Diagram of EPR tube assembly. The spin
labeled sample is pipetted up and kept in the loading tip. This loading tip is inserted into the top, open end
of the EPR tube with the opposite side sealed off using a Bunsen burner. The EPR tube with loading tip
is then placed into a 15 mL tube which is inserted into a centrifuge adaptor, where it is briefly centrifuged.
This will make the sample to evacuate the loading tip and fill the EPR tube from the bottom to the top.
After centrifugation, the tube is cleaned with ethanol and dried with a Kimtech wipe. The sample is now
ready for EPR.
tube without the cap. The 15 mL tube is used as an adaptor to centrifuge the sample in the
loading tip into the EPR tube. Place 15 mL tube in a clinical centrifuge at the maximum
speed for 30 seconds. The protein solution should have moved from the EPR loading tip and
be settled at the bottom part of the EPR capillary tube. Clean the EPR capillary tube by
dipping it in ethanol and drying with a Kimtech wipe. Place the EPR capillary tube in the
loop-gap resonator and collect the spectrum. Measure EPR spectra (see Note 12).
2. Spectral subtraction. The process is summarized in Figure A.4. All data analysis is per-
formed in Brukers EPR suite Xepr vs. 2.6b.54. Collect the EPR spectrum of uncomplexed
(or unbound) SNARE and that of the SNARE complex. The former has a narrow lineshape,
reflective of freely moving random coil while the latter has a composite (narrow + broad)
lineshape, reflective of the equilibrium coexistence of a random coil species and the struc-
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tured SNARE complex (Figure A.4A). Process the spectra using the baseline correction and
the normalization functions of the Xepr software suite. After processing, both spectra are
brought back to the derivative spectral mode by double derivatization for direct comparison
(Figure A.4B). Baseline correction is usually performed using a 1st order polynomial linear
fit to the 20 outermost data points on either end of the spectra. Center and overlay two
spectra on top of each other (Figure A.4C). Adjust the gain of the unbound spectrum so
that the height of the 3rd peak in the unbound spectrum roughly match the height of the
shape component of the 3rd peak in the composite spectra. Subtract the unbound from the
composite to obtain the bound fraction spectrum (Figure A.4E). Adjust the gain carefully to
yield a smooth, broad spectrum, reflecting the bound species. The adjusted gain is equivalent
to the percentage of unbound population in the composite spectrum.
A.5 Notes
1. When using site-directed spin labeling to study a change in structure or conformation, an
important criterion is that the label will minimally interfere with the native structure or
binding sites. Specifically for SNARE proteins, sites are chosen to introduce cysteines that
face the outside of the four-helical bundle. Primers are designed according to the Agilent
QuikChange II Site-Directed Mutagenesis Kit protocol (QuikChange II Site-Directed Muta-
genesis Kit: Instruction Manual). The most effective primers are ∼33 nucleic acid-long (15
before the site of desired mutagenesis, then the cysteine codons (TGT or TGC), and 15 after
the site of mutagenesis). When necessary, the length of the primer can be extended with
native nucleotides, so that the primers begin and end with multiple G or Cs to allow for
tighter annealing (e.g. GC, CC, GG, and CG). The Northwestern Oligonucleotide Proper-
ties Calculator (Kibbe (2007)) is used to measure GC%, melting temperature, and test for
self-complementarity for generated primers. Normally, the GC% and melting temperature
are satisfactory according to the Agilent QuikChange protocol (QuikChange II Site-Directed






Figure A.4: Spectral subtraction analysis. (A) Raw unbound EPR spectrum (red) and raw composite
(mixture of labeled unbound species with interacting species) EPR spectrum (purple) are obtained directly
from EPR. (B) Both spectra are baseline-corrected and normalized. (C) The processed unbound and
composite spectra are centered and overlayed on top of each other. The point of comparison between
the two spectra is the 3rd peak indicated by the arrow. The unbound spectrum has a higher intensity
representing the spectrum when 100% are unbound. (D) The gain of the unbound spectrum is coarsely
adjusted, so the height of the 3rd peak matches the composite spectra. (E) The gain is finely adjusted, so
the spectral subtraction results in a bound spectrum (blue) that is smooth and broad. The total adjusted
gain is equivalent to the percentage of unbound population within the composite spectra. This can be used
to calculate the bound population in the composite spectra as well.
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common problem is with self-complementarity. To address this issue, the codon either right
before or after the introduced cysteine is changed to an alternative codon for the same amino
acid in E. coli. Once the issue is resolved, the reverse complementary primer sequence is
obtained from the same web page. The primers for our studies are synthesized by the Iowa
State DNA facility.
2. When using a new plasmid, controls are necessary to ensure a proper transformation. The
method is adapted from the Addgene heat-shock transformation protocol (Addgene: Bacterial
Transformation). Transformations are grown on LB-agarose antibiotic plates. A positive
control is performed by transforming and plating a plasmid with a known antibiotic resistance
to test for competency of cells. A negative control is performed by plating the competent
cells directly on an ampicillin agar LB plate to verify absence of native resistance. If the
transformed SNARE colonies have not formed within 24 hrs., repeat the transformation. If
colonies still do not form, repeat the PCR reaction. If colonies still do not form, design new
primers.
3. Phosphate-buffered saline (PBS) at pH 6.85 is the lysis buffer for soluble proteins (SNAP-
25). Phosphate-buffered saline with triton X-100 (PBST) at pH 6.85 is the lysis buffer for
membrane proteins (syntaxin-1A (stx), VAMP2 or synaptobrevin 2 (VpF)). Phosphate buffers
are preferred over tris-base buffers due to the unfavorably low MTSSL-cysteine reactivity in
the presence of tris. The pH of PBS is set to 6.85 to reduce nonspecific labeling (e.g. to
amines) at more basic pH levels. The elution buffer for soluble proteins is the same as the
lysis buffer. The elution buffer for membrane proteins is phosphate-buffered saline 0.8%-
ocytl-β-Glucoside (PBS-OG) at pH 6.85.
4. When a new protein is purified for the first time, it is advised that every step in the purification
process be checked. This has proven to be especially true when purifying SNARE proteins in
the manner described. A SDS-PAGE gel can easily help track the progress in the purification
of the protein of interest by saving an aliquot after each step. 10 µL is saved from the
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resuspended cells before lysis, the lysate, the supernatant and pellet after centrifugation, the
flow through as the supernatant leaves the column in step, the washed beads before cleavage
and after cleavage, and the eluted protein. Dilute the aliquots taken from resuspended cells,
lysis, supernatant, pellet, and flow through to 50 µL with the lysis buffer. Take 10 µL of each
of these, add 2.5 µL of 5X SDS-PAGE loading dye, and boil for 10 min. During the boiling
process, do not let the caps of the Eppendorf tubes pop open. Perform a quick spindown to
gather all the liquid back to the bottom of the tube. Add 2.5 µL of 5X SDS-loading dye to
the other undiluted saved aliquots. Load and run the entire sample for each step using a 15%
SDS-PAGE gel along with a ladder.
The SDS-PAGE gel is also useful for determining the efficiency of the SNARE protein purifi-
cation. If the resuspended cells or lysate do not contain large amounts of SNARE protein,
try performing a fresh transformation. It is advised to make a fresh transformation for every
expression. If the majority of the SNARE protein is in the pellet, this usually means that
the cells are not sufficiently lysed. It can also mean that the expression temperature was too
high, which can produce inclusion bodies. If neither of these solutions resolve the issue of
low yield, then the detergent concentration for the PBST lysis buffer can be increased. This
will weaken the lipid membrane of the cells allowing for a more efficient lysis. If a signifi-
cant amount of SNARE protein is in the flow through, there is most likely an issue with the
amount of effectiveness of the affinity beads. If the protein appears impure on beads prior
to cleavage, additional washes are needed. If the majority of SNARE protein remain on the
beads after cleavage, then try increasing the salt concentration in the elution buffer. The salt
concentration can be increased up to a maximum of 500 mM for effective elution. If the eluted
fractions contain higher molecular weight impurities, this is most likely due to the residual
amounts of thrombin in solution. 1 µL of AEBSF (200 mM) is added to each 1 mL elution to
deactivate the residual thrombin.
5. The ideal labeled SNARE protein concentration for EPR is 50 µM. Using our method of spin
labeling, consecutive steps of spin concentrations and PD-10 desalting columns are necessary.
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Each time one of these steps is performed, a small amount of protein is lost, decreasing the
labeled protein concentration. In EPR experiments, the labeled proteins are mixed with
unlabeled SNARE partners to form the SNARE complex. The mixing of the two or three
proteins also decreases the labeled protein concentration. To address these issues, the SNARE
proteins are aliquoted into stock concentrations well above 50 µMM. It is preferable to store
150 µL aliquots at a concentration greater than 100 µM protein.
6. The nitroxide spin label (MTSSL) is dissolved in an acetonitrile solution. Acetonitrile may
cause proteins to aggregate and fall out of solution, so it is ideal to limit the amount that is
added when spin labeling. The 20 mM MTSSL stock is recommended when using volumes
equal to or less than 20 µL. If a larger volume is required, use the 100 mM stock. It is also
important to add MTSSL to the protein instead of vice-versa. This way the protein is able
to interact with the most dilute amount of the acetonitrile preventing aggregation.
7. A 200 mM stock solution of TEMPOL is made by dissolving 344 mg of 4-Hydroxy-TEMPOL
(Sigma Aldrich) in 100 mL of ddH2O. This is quantitatively made in a volumetric flask. This
stock solution is diluted to generate the TEMPOL standard solutions at 10, 25, 50, 75, and
100 µM. These concentrations cover the concentration range of the raw SNARE proteins
when purified. The standards must generate a linear curve with an R2 value of 0.95 or higher
for an accurate measurement.
8. When drying the lipids in the glass tube, start with soft air pressure while constantly rotating
the glass tube. This generates a thin lipid film that forms around the inner edge, ideally on
the bottom centimeter of the tube. Once the film has mostly dried, increase the air pressure
to ensure the lipids are completely dried. It is important to apply soft pressure initially to
avoid clumping the lipids at the bottom of the tube. Clumped lipids are found to generate
inconsistent vesicles. After the lipids are fully dried, a Kimtech wipe is rubber banded across
the opening of the tube to prevent particulates from entering. This is then stored in the dark
inside a vacuum desiccator at room temperature overnight (16-18 hrs.).
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9. Prior to reconstitution, the t-SNARE proteins, Stx and SN25, are premixed and incubated
for 30 minutes at room temperature. Since SN25 is not a membrane protein, PBS (10%
OG) is added to maintain the detergent concentration in the solution above critical micelle
concentration (0.08%). The mixture of Stx : SN25 : PBS (10% OG) is added at a ratio of
1 : 1.5 : 0.12. An excess amount of SN25 is used in comparison to Stx in order to prevent
formation of an off-pathway 2 : 1 complex. After incubation, the t-SNARE complex is stored
on ice until needed.
10. His-Apo-A1 is in a pET28b vector and GST-Apo-A1 is in a pGEX-KG vector. Both are
recombinantly expressed in E. Coli BL21 DE3 cells grown in 500 mL of LB medium with
either kanamycin (50 µg/ml) for His-Apo-A1 or ampicillin (100 µg/ml) for GST-Apo-A1 at
37 ◦C and 200 rpm to an OD600 of 0.6-0.8. Once at the optimal OD600, the cells are induced
with 150 µL of IPTG (1 M) and grown for an additional 16-18 hrs. at 16 ◦C. The cells are
pelleted at 3,800 x g and 4 ◦C for 10 minutes in a JA-14 rotor and then, resuspended in ∼15
ml of lysis solution. The lysis solution should consist of PBS pH 7.4 along with 2.5 mM DTT,
60 µM AEBSF, and 0.15% N-lauroylsarcosine (with 20 mM imidazole for his-Apo-A1). The
cells are lysed with 3 passes through a cell homogenizer. The lysate is spun down at 27,200
x g and 4 ◦C for 30 min. in a JA-25.5 rotor. ∼1 ml of the affinity beads are equilibrated
in a 25 mL batch column with their respective lysis buffers while the cells are centrifuging,
Ni-NTA Agarose (his-Apo-A1) or GSH beads (GST-Apo-A1). The supernatant is then added
to the beads and nutated at 4 ◦C for 2 hrs. The supernatant is drained from the columns
and the beads are washed with 5 CV PBS pH 7.4 (with 20 mM imidazole for his-Apo-A1).
His-Apo-A1 is eluted with PBS pH 7.4 with 200 mM imidazole 1 mL at a time. Significant
amounts of protein are found in fractions 2-4. The GST-Apo-A1 is cleaved off of the GSH
beads by incubating with 30U of thrombin in 1 mL of PBS for 2 hrs. at room temperature
and eluting 1 mL at a time in the same buffer. 177 µL of glycerol is added to each 1 mL
eluted fractions of both types of Apo-A1 to have a final concentration of 15% glycerol. After
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the concentration has been checked, they are divided in stock concentrations and stored at
−80 ◦C. These remain active for ∼1 year.
11. The solution of bio-beads needs to be thoroughly resuspended before measuring out bio-beads
because they quickly fall out of solution. Pipetting bio-beads is made much easier if the last
third of a 200 µL tip is cut off. It is easiest to collect the supernatant from the bio-beads if a
small cavity is made in the pelleted bio-beads. This is done by decanting a small amount of
the supernatant with a pipette tip, submerging the tip below the bio-beads layer, injecting
the supernatant from the tip to create a cavity, moving the pipette tip to the bottom of the
tube, and then quantitatively decanting all the supernatant from the cavity. This method
prevents bio-beads from clogging the pipette tip while decanting the supernatant.
12. Spectra are collected at 1 mW incident microwave power using a field modulation of 2 Gauss
at 100 kHz. The scans are performed at room temperature with a scan width of 120 Gauss
and 1024 data points per scan. The time constant is set to 40.96 msec and conversion time
of 40.96 msec. 20 scans was sufficient to obtain a clear EPR spectra.
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APPENDIX B. A DIFFERENT PERSPECTIVE
We will end where every good story does. Remembering the journey and looking forward to
what is coming. We first met α-synuclein as a small protein found in our brains. It is highly
expressed and tightly regulated. For a long time it was thought to cause Parkisons. Its aggregates
are definitely toxic: they interfere with neurotransmission and cause cell death. Doesnt sound like
a cool cat, but that isnt the whole story. Researcher were trying to understand how α-synuclein
aggregates disrupt intercellular communication and found out what α-synuclein is really like. It
can float in solution, but it prefers to hug membranes. It isnt too snobby, but it does prefer
membrane that are negatively charged and have some curvature to them. It also likes to hang
with the SNARE complex. It uses its c-terminal to high five the v-SNARE VAMP2. Shortly after
their friendship went facebook official people started to really delve into their relationship. There
were mixed opinions: some people thought that α-synuclein was nothing but trouble the SNARE
complex, but others were convinced that the two worked well together. It is pretty clear that when
α-synuclein aggregates it gets in the way of the SNARE complex, but Lou showed that all that was
required for the two to work together was balance. Then some busybodies by the name of Hawk
and Khounlo really started sticking their nose into α-synuclein and SNAREs relationship; really
trying to figure out how the two worked together. Those nosey punks noticed that α-synuclein
made SNARE way more active. Now the SNARE complex is a complicated character. It doesnt
fit in a box with other enzymes. It doesnt use chemical energy to function, but relies on energy
from folding. By folding it can bring two membrane together: for better or worse. The question
was how does α-synuclein affect this? After some poking around the guys found that α-synuclein
seemed to work like hitch; he just set the happy couple up making SNAREs job easier. It didnt
meddle with the rest of the process. Some other bloke named Logan was getting nosy too. He
found something that seemed to say that α-synuclein did help the happy couple get further down
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the road. Cells expressing lots of α-synuclein were better able to dump their cargo. He thought
that maybe α-synuclein was giving SNARE a hand with the ceremony by like maybe working the
teleprompter: just speed up the process and making it more efficient. Hawk and Khounlo found out
that in reality it made room for more SNARE complex to get involved in the joining of membranes.
Imaging that: the happy membranes getting merged by a slew of SNARE complexes all at once.
What would you do it that happened to you? It does seems that α-synuclein does help SNARE get
its job done. The question is then why does it aggregate? Does it just get old or maybe gummy?
Or is there another party involved that keeps α-synuclein in line: maybe like a chaperone that at
some point throws in the towel? When one α-synuclein gets too set on hanging out with another
α-synuclein the chaperone splits them up and sends them on their way. What if it was actually the
chaperone that retired and gave up trying to keep α-synuclein working how it should? Stay tuned
for the next instalment of science sitcom weekly. Who will this chaperone be? What will their true
intentions be for α-synuclein and how does it keep it functioning right? Most importantly, what
causes it to go into retirement?
